Regulatory t cells with chimeric antigen receptors targeting costimulatory molecules for prevention and / or treatment of inflammatory disorders
CAR-Tregs targeting OX40L co-stimulatory molecules in regulatory T cells address the limitations of current treatments by providing a sustained immune suppression and improved therapeutic efficacy for inflammatory disorders and GVHD.
Patent Information
- Application Number
- CN202380036930.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-28
- Filing Date
- 2023-02-28
- Publication Date
- 2024-12-06
AI Technical Summary
Current treatments for inflammatory conditions and graft-versus-host disease (GVHD) involve immunosuppressive therapy, which can cause serious side effects, and there is a need for more effective engineered T cells, particularly regulatory T cells (Tregs), to prevent autoimmunity and transplant rejection without adverse effects.
Development of chimeric antigen receptors (CARs) in regulatory T cells (Tregs) that specifically target OX40L co-stimulatory molecules, using a synthetic FoxP3 promoter to limit CAR expression and enhance suppression of abnormal immune responses, with CAR-Tregs providing a sustained blockade of cytokine production during inflammation.
CAR-Tregs effectively target a wide range of inflammatory conditions and autoimmune disorders, restoring immune tolerance and maintaining a balance between conventional T cells and Tregs, offering a superior therapeutic alternative to antibodies.
Smart Images

Figure CN119095869A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Pursuant to 35 U.S.C. §119(e), this application claims the benefit of U.S. Provisional Application No. 63 / 314,789, filed on February 28, 2022, the contents of which are incorporated herein by reference in their entirety. Government support
[0002] This invention was made with government support under Grant Nos. HL095791 and AI051731 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Technical Field
[0003] The technology described herein relates to chimeric antigen receptor (CAR) constructs, for example, in regulatory T cells (Tregs) that target co-stimulatory molecules. Background Art
[0004] The main causes of inflammatory conditions or autoimmunity and graft rejection after organ transplantation or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HCT) are autoreactive and alloreactive T cells that attack the patient's or donor's organs or tissues. Current treatments for preventing autoimmunity, transplant rejection, and GVHD involve strict immunosuppressive therapy, which itself can lead to serious, unnecessary side effects. In order to prevent autoimmunity, transplant rejection, and GVHD without causing unnecessary side effects, it would be beneficial to be able to use engineered T cells, particularly engineered regulatory T cells (Tregs) to treat patients receiving organ transplants.
[0005] Tregs suppress the immune response of other cells. These cells inhibit T cell proliferation and cytokine production and can prevent autoimmunity or shut down the immune response after successfully eliminating an invading organism. They come in several forms, the most well-known of which are those that express CD4, CD25, Foxp3, and Helios (CD4 + CD25 + Engineering Tregs and directing Tregs to appropriate targets can enhance the suppression of abnormal immune responses. Summary of the invention
[0006] As described herein, chimeric antigen receptors (CARs) provide a promising method for targeting APCs and OX40L co-stimulatory molecules. CARs are engineered receptor proteins in which the natural recognition portion is removed and replaced with a specific recognition portion that redirects the protein to the target and binds to a specific protein. T cells expressing CARs are called CAR-T. CARs and CAR-Ts are most commonly used to treat tumors and cancers, and to a lesser extent for the treatment of inflammatory conditions, but more effective CARs are still needed to minimize or eliminate the undesirable immune response to the underlying causes of inflammatory conditions and autoimmune disorders. The generation of OX40L CAR-Tregs is intended to provide a more sustained blockade of cytokine production during inflammation or autoimmune triggering. Compared with a few newly developed CAR-Tregs targeting specific antigens (such as HLA-A2, CEA, and CD83), CAR-Tregs targeting OX40L cover a wider range of inflammatory conditions and provide a wider range of applications. Furthermore, activated Tregs help restore immune tolerance and maintain a balance between conventional T cells (Tcon) and Treg functions, making OX40L CAR Treg cells an alternative or better agent than antibodies for treating inflammatory disorders or autoimmune diseases.
[0007] As described herein, the present inventors have produced human regulatory T cells (Treg) engineered to express chimeric antigen receptors (CARs) specifically targeting OX40L. In some embodiments, described herein is a CAR comprising an extracellular recognition portion (e.g., scFv) containing an anti-OX40L antibody reagent and an intracellular signaling region to allow or induce CAR-Treg cell activation after binding to the OX40 ligand on APCs. In addition, in order to limit the harmful effects of Tcon activation contamination (contamination) during the purification and amplification of Treg cells, a synthetic FoxP3 promoter drives CAR expression. This promoter limits the CAR expression of Treg cells. Therefore, these CAR-Treg and related compositions can be used in therapeutic methods to treat diseases described herein.
[0008] In one aspect of any embodiment, described herein is a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus: (a) an extracellular recognition portion that specifically binds to OX40L; (b) a transmembrane portion; and (c) an intracellular signaling portion.
[0009] In some embodiments of any of these aspects, the C-terminus of the intracellular signaling portion of the CAR further comprises a detectable polypeptide.
[0010] In some embodiments of any of these aspects, the detectable polypeptide of the CAR is a fluorescent polypeptide.
[0011] In some embodiments of any of these aspects, the fluorescent polypeptide of the CAR is NeonGreen.
[0012] In some embodiments of any of these aspects, the CAR further comprises a cleavage site between the intracellular signaling moiety and the detectable polypeptide.
[0013] In some embodiments of any of these aspects, the cleavage site of the CAR is a cleavable T2A site or a tandem P2A-T2A site.
[0014] In some embodiments of any of these aspects, the recognition portion of the CAR is an antibody agent or a ligand functional domain.
[0015] In some embodiments of any of these aspects, the antibody agent of the CAR is a scFV.
[0016] In some embodiments of any of these aspects, the antibody agent of the CAR is an anti-OX4L antibody agent.
[0017] In some embodiments of any of these aspects, the antibody reagent of the CAR comprises a CDR sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the 6 CDRs of SEQ ID NOs: 1-6.
[0018] In some embodiments of any of these aspects, the antibody reagent of the CAR comprises a sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the amino acid sequence of SEQ IDNOs:7-12.
[0019] In some embodiments of any of these aspects, the intracellular signaling portion of the CAR comprises one or more of the following: a CD28 co-signaling domain, a 41BB co-signaling domain, an IL2RαJAK3 and IL2RβSTAT5 composite docking site, a TGFβ-R SMAD2 / 3 docking site, and a CD3ζ signaling domain.
[0020] In some embodiments of any of these aspects, the intracellular signaling portion of the CAR comprises a CD28 co-signaling domain and a CD3 zeta domain.
[0021] In some embodiments of any of these aspects, the intracellular signaling portion of the CAR comprises a 41BB co-signaling domain and a CD3 zeta domain.
[0022] In some embodiments of any of these aspects, it is a nucleic acid molecule encoding a CAR.
[0023] In some embodiments of any of these aspects, expression of the nucleic acid molecule is controlled by a Treg-specific promoter or a MND promoter.
[0024] In some embodiments of any of these aspects, the Treg-specific promoter of the nucleic acid molecule encoding the CAR comprises a FoxP3 promoter or a hybrid promoter of FoxP3 and IKZF2 / Helios.
[0025] In some embodiments of any of these aspects, it is a vector comprising a nucleic acid molecule encoding a CAR.
[0026] In some embodiments of any of these aspects, it is a cell comprising: a CAR, or a nucleic acid molecule encoding the CAR, or a vector comprising a nucleic acid molecule encoding the CAR.
[0027] In some embodiments of any of these aspects, the cell is a Treg.
[0028] In some embodiments of any of these aspects, the Tregs express Foxp3.
[0029] In some embodiments of any of these aspects, the Tregs express CD4 and CD25.
[0030] In some embodiments of any of these aspects, it is a population of cells, at least 80% of which are cells of any of these aspects.
[0031] In some embodiments of any of these aspects, there is a method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a cell or population of cells having any of these aspects.
[0032] In some embodiments of any of these aspects, the autoimmune or inflammatory disorder comprises allogeneic or xenogeneic transplant rejection, or graft-versus-host disease (GVHD).
[0033] In some embodiments of any of these aspects, the autoimmune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection, and an inflammatory disorder.
[0034] In some embodiments of any of these aspects, the Treg population is autologous to the subject.
[0035] In some embodiments of any of these aspects, the Treg population is allogeneic to the subject.
[0036] In some embodiments of any of these aspects, a cell or population of cells for use in a method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof comprises administering the cell or population of cells to the subject.
[0037] In some embodiments of any of these aspects, the autoimmune or inflammatory disorder comprises allogeneic or xenogeneic transplant rejection, or graft-versus-host disease (GVHD).
[0038] In some embodiments of any of these aspects, the autoimmune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection, and an inflammatory disorder.
[0039] In some embodiments of any of these aspects, the Treg population is autologous to the subject.
[0040] In some embodiments of any of these aspects, the Treg population is allogeneic to the subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1A-Figure 1D The construction and expansion of OX40L CAR-Treg cells are shown. ( Figure 1A) Schematic diagram of Treg-specific chimeric antigen receptor (CAR) encoding construct: A single-chain fragment variant of the antigen-binding fragment derived from an anti-OX40L antibody is connected to the intracellular CD3ζ and 4-1BB or CD28 signaling domains, and is connected to the fluorescent protein reporter NeonGreen through a cleavable T2A site. The expression of CAR and fluorescent reporter protein is controlled by a Treg-specific promoter or a synthetic nonspecific MND promoter. A construct encoding only NeonGreen under a Treg-specific promoter or MND promoter is used as a control. ( Figure 1B ) Illustration of cell surface expression of OX40L-specific CAR constructs: In vitro binding of OX40L soluble protein to the cell surface of Jurkat lymphocytes was observed in >85% of NeonGreen-positive cells (successfully transduced with a construct encoding the CAR / reporter), while cells transduced with a construct encoding NeonGreen showed only negligible binding of OX40L protein. ( Figure 1C ) Human FACS-purified CD25+CD127- Treg cells were transduced with OX40L-specific CAR constructs with signaling CD3ζ / 4-1BB (BBz) or CD3ζ / CD28 (28z) domains under the control of a FoxP3-specific promoter, and then expanded in vitro with CD3 / CD28 microbeads and IL-2. The bar graph describes the normal expansion of CAR-transduced Treg cells. ( Figure 1D ) Amplified human Treg cells stably express CAR constructs controlled by FoxP3 promoter. CD25+CD127-Treg and CD25-CD127+ conventional CD4 (Tconv) cells purified by human FACS are transduced with OX40L-specific CAR constructs, which have signaling CD3ζ / 4-1BB (BBz) or CD3ζ / CD28 (28z) domains under the control of FoxP3-specific promoters, and then amplified in vitro with CD3 / CD28 microbeads and IL-2. The percentage of NeonGreen+ cells in Treg and Tconv cell cultures was assessed at different time points by flow cytometry. The figure illustrates that the CAR construct controlled by FoxP3 promoter is stably expressed in Treg cells, while in resting Tconv cells, the expression of the CAR construct decreases after the removal of CD3 / CD28 beads (D18).
[0042] Figure 2A-2D Shown is the ex vivo large-scale expansion of OX40L CAR-Tregs. ( Figure 2A ) Schematic diagram of large-scale CAR-Treg cell expansion experiment. ( Figure 2B) Efficacy of the lentiviral transduction procedure: Human FACS-purified CD25+CD127- Treg cells and CD25-CD127+ Tconv cells were transduced with lentivirus containing genetic constructs encoding the NeonGreen reporter fluorescent protein or CAR fused to the NeonGreen reporter (see Figure 1A ). The percentage of NeonGreen+ cells in Treg and Tconv cultures on day 13 was determined by flow cytometry. ( Figure 2C ) Ex vivo large-scale expansion of CAR-Treg cells: Untransduced human Treg cells or Treg cells transduced with NeonGreen reporter or CAR constructs were expanded ex vivo for 34 days. This figure shows that Treg cells expressing CAR have similar expansion capacity. ( Figure 2D ) Human CAR-Treg cells expanded in vitro showed stable FoxP3 expression. CD25+CD127-Treg cells purified by human FACS were transduced with BBz or 28z CAR constructs or with NeonGreen reporters and expanded in vitro using CD3 / CD28+IL-2. The expression of FoxP3 protein was determined by flow cytometry, and it was confirmed that the expression of FoxP3 in CAR-Treg cells was at the same level as that in endogenous Treg control cells.
[0043] Figure 3A-3C The functional characteristics of CAR-Treg cells are shown. ( Figure 3A )CAR stimulation induces expression of Treg activation / suppression markers: Treg cells transduced with BBz or 28z CAR constructs were stimulated in vitro by CAR (by co-culturing with K562 cells expressing OX40L (K562-L)) or by endogenous TCR (by co-culturing with CD3 / CD28 activation beads). Anti-OX40 antibodies were added to Treg / K562-L cultures (K562-L+Ab) to block potential signaling through the endogenous OX40L / OX40 pathway, and thus confirmed that CAR-Treg cells were stimulated by CAR. The figure illustrates that the induction of CAR-mediated Treg activation / suppression markers (CTLA4, LAP, CD71, GARP, and LAG-3) is at levels comparable to TCR stimulation. ( Figure 3B)CAR stimulation induces production of the Treg-supportive cytokine IL-2, but not pro-inflammatory cytokines: Treg cells expressing BBz and 28z CARs were stimulated in vitro by CAR (K562-L) or endogenous TCR (CD3 / CD28 beads). Anti-OX40 antibody was added to Treg / K562-L cultures to block potential signaling through the endogenous OX40L / OX40 pathway. The figure illustrates CAR-mediated induction of IL-2 production, while production of pro-inflammatory cytokines IFNg-γ, TNF-α, and IL-17A remained unaffected. ( Figure 3C )CAR stimulation improves the suppressive function of Treg cells in vitro: Control Treg cells and Treg cells expressing BBz or 28zCAR were co-cultured with CD3 / CD28 bead-activated conventional CD4 T cells (CD4 Tconv) in the presence or absence of K562 cells expressing OX40L (K562-L and K562, respectively). Flow cytometry was used to assess the suppressive capacity of Treg cells by relative inhibition of CD4 Tconv proliferation. The figure depicts the increased suppressive capacity of CAR-Treg cells co-cultured with K562 cells expressing OX40L.
[0044] Figure 4 The proposed suppressive mechanism of OX40L CAR-Tregs is shown
[0045] Figure 5A - Figure 5C shows the effect of blocking OX40L in a mouse transplant model. ( Figure 5A ) Evaluate the effect of anti-human OX40L (hOX40L) treatment on CD8 + Schematic representation of the experimental design for the effects on T cell function. Figure 5B ) Purification of human CD8 from mouse spleen + T cells. U937 cells and CD8 + After 4 h of T cell incubation, the percentage of specific lysis was assessed by measuring fluorescence intensity. Error bars represent mean ± SD (n = 5 mice / group), and data represent three independent experiments. Statistical significance was determined using Sidak's two-way ANOVA test. ns, not significant. (Fig. 5C) Clinical scores and survival of hPBMCs mouse recipients after anti-hOX40L treatment.
[0046] Figure 6 Anti-OX40L / sirolimus prophylaxis induces long-term GVHD-free survival after allogeneic HCT.
[0047] Figure 7Schematic diagrams of constructs encoding Treg-specific CARs or control constructs encoding NeonGreen are shown.
[0048] Figure 8A-B The expression of OX40L-CAR construct is shown. ( Fig. 8A ) Schematic diagram of the generation of Ox40L CAR-Tregs. ( Figure 8B ) Surface expression of FOXP3-driven OX40L-CAR and FOXP3-driven NeonGreen control constructs.
[0049] Figure 9A-9B Stable and selective expression of OX40L-CAR Tregs is shown. Fig. 9A ) The determination of FOXP3 positive signals in CD+ cells showed similar percentages in Treg, Neon-Treg and CAR-Treg, indicating the stability of CAR-Treg after 23 days of ex vivo expansion. Fig. 9B ) Determination of NeonGreen positive signals in CAR-Treg compared with CAR-Tcon indicated that FOXP3 promoter activity in Treg was stable and selective.
[0050] Figure 10A-10B Shown are the effects of OX40L CAR-Treg on Treg suppressor proteins and pro-inflammatory cytokines. ( Fig. 10A )Schematic diagram of OX40L-specific CAR-Treg activation. Fig. 10B ) After viral transduction, OX40L CAR-Tregs and control Neon-Tregs were co-cultured with irradiated WT K562 cells or K562 cells expressing OX40L. After 48-72 hours, the expression of the indicated cytokines or suppressor proteins was detected by flow cytometry.
[0051] Figure 11A-11B CAR-Tregs were shown to suppress T cell expansion in vitro. Fig.11A ) Schematic diagram of the Treg suppression assay setup. ( Fig. 11B ) Determination of the percentage of CD4 suppression in response to different Treg:Tresponder ratios showed that activated CAR-Tregs more effectively suppressed T cell expansion in vitro through OX40L engagement.
[0052] Figure 12A-12B CAR-Tregs were shown to suppress T cell expansion in MLR. ( Fig. 12A ) Schematic diagram of the MLR inhibition assay. Fig. 12B) Determination of the percentage of CD4 suppression in response to different Treg:Tresponder ratios showed that CAR-Tregs suppressed MLR compared to Neon-Tregs.
[0053] Figure 13A-13B Shown is the effect of OX40L CAR-Treg on a GVHD mouse model. ( Fig.13A ) Xenogeneic GVHD experimental setup. Fig. 13B ) Human PBMCs isolated from healthy donors were retro-orbitally injected into sublethally irradiated NSG mice alone or together with control Neon-Tregs or OX40L CAR-Tregs. The mice were monitored twice a week for weight loss, GvHD scores, and survival endpoints. Both Neon-Tregs and OX40L CAR-Tregs delayed the onset of GvHD, but OX40L CAR-Tregs showed significantly reduced GvHD clinical scores and improved overall survival. ***p<0.001. DETAILED DESCRIPTION
[0054] Described herein is a chimeric antigen receptor (CARs) engineered in regulatory T cells (Tregs), and its specific targeting co-stimulatory molecules, for example, OX40L. The technology described herein can cause blocking of OX40-OX40L interactions, and is effective in many inflammatory conditions, autoimmune diseases, and graft-versus-host disease (GVHD). OX40LCAR-Tregs restore immune tolerance and maintain the functional balance of conventional T cells (Tcon) and Tregs, thereby providing additional, alternative or superior therapeutic agents for the above-mentioned diseases. Polynucleotides and vectors encoding the CAR polypeptides, cells expressing the CAR polypeptides, pharmaceutical compositions comprising the CAR polypeptides, and methods using the CAR polypeptides are also described herein.
[0055] Thus, in one aspect of any embodiment, described herein is a chimeric antigen receptor (CAR) polypeptide comprising, from N-terminus to C-terminus: a. an extracellular recognition portion that specifically binds to one or more co-stimulatory molecules (e.g., OX40L); b. transmembrane portion; and c. Intracellular signal transduction part.
[0056] CARs are receptor proteins engineered to include exogenous recognition domains that specifically bind to desired targets (e.g., OX40L). Therefore, cells expressing or comprising such CARs provide the ability to target desired targets. The receptors are chimeric because they combine antigen binding and immune cell activation functions into a single receptor in a combination that does not occur in nature, and / or because they combine antigen binding sequences and immune cell activation sequences from different genetic sources. In some embodiments of any aspect, the extracellular recognition portion of CAR described herein does not naturally exist in a protein comprising an intracellular signaling portion described herein.
[0057] In some embodiments of any aspect, CAR described herein includes an extracellular recognition portion. As used herein, "extracellular recognition portion" refers to a polypeptide sequence that binds to a target, and when CAR is expressed in a cell, the polypeptide sequence will be displayed on the extracellular side of the cell membrane. In some embodiments of any aspect, the extracellular recognition portion includes an antibody, an antibody reagent, an antigen-binding fragment thereof, a F (ab) fragment, a F (ab') fragment, a single-chain variable fragment (scFv) or a single domain antibody (sdAb). In some embodiments of any aspect, the extracellular recognition portion is monovalent, divalent or multivalent. In some embodiments of any aspect, the extracellular recognition portion includes a human, humanized or chimeric antibody or antibody reagent.
[0058] Antibody reagents are specific for targets and / or markers as described herein, for example, T cell co-stimulatory molecules. Such reagents are easily commercially available. In some embodiments of any aspect, the extracellular recognition portion may be an antibody reagent comprising one or more (e.g., one, two, three, four, five or six) CDRs of any antibody described herein or known in the art. In some embodiments of any aspect, for targets and / or markers as described herein (e.g., specifically bound to T cell co-stimulatory molecules as described herein), specific antibody reagents may be antibody reagents comprising six CDRs of any antibody described herein or known in the art. In some embodiments of any aspect, for targets and / or markers as described herein (e.g., specifically bound to T cell co-stimulatory molecules as described herein), specific antibody reagents may be antibody reagents comprising three heavy chain CDRs of any antibody described herein or known in the art. In some embodiments of any aspect, for targets and / or markers described herein (e.g., specifically bound to T cell co-stimulatory molecules described herein), specific antibody reagents may be antibody reagents comprising three light chain CDRs of any antibody described herein or known in the art. In some embodiments of any aspect, for targets and / or markers described herein (e.g., specifically bound to T cell co-stimulatory molecules described herein), specific antibody reagents may be antibody reagents comprising VH and / or VL domains of any antibody described herein or known in the art. In some embodiments of any aspect, for targets and / or markers described herein (e.g., specifically bound to T cell co-stimulatory molecules described herein), specific antibody reagents may be antibody reagents comprising VH and VL domains of any antibody described herein or known in the art. Such antibody reagents are particularly contemplated for use in methods and / or compositions described herein.
[0059] As used herein, "antibody variable region" refers to the portion of the light chain and heavy chain of an antibody molecule, which includes the amino acid sequences of the complementary determining regions (CDRs; i.e., CDR1, CDR2, and CDR3), and framework regions (FRs). VH refers to the variable region of the heavy chain. VL refers to the variable region of the light chain. For the methods and compositions described herein, the amino acid positions assigned to CDRs and FRs can be defined according to Rabat (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991)). The amino acid numbering of antibodies or antigen-binding fragments is also based on Rabat numbering.
[0060] The terms "antigen binding fragment" or "antigen binding domain" used interchangeably herein refer to one or more fragments of a full-length antibody that retain the ability to specifically bind to a target of interest (e.g., specifically bind to a T cell co-stimulatory molecule described herein). Examples of binding fragments included in the term "antigen binding fragment" of a full-length antibody include: (i) a Fab fragment, a monovalent fragment consisting of a VL, VH, CL, and CH1 domain; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) an Fv fragment consisting of a VH and CH1 domain; (iv) an Fv fragment consisting of a single-arm VL and VH domain of an antibody; (v) a dAb fragment (Ward et al., (1989) Nature 341: 544-546; the contents of which are incorporated herein by reference in their entirety), consisting of a VH or VL domain; and (vi) an isolated complementary determining region (CDR) that retains specific antigen binding function. The sequences derived from the light chain and heavy chain, respectively, may be provided in the order from N-terminus to C-terminus, or in the reverse order.
[0061] Co-stimulatory molecules are a group of cell surface molecules that amplify or counteract the initial activation signal that T cell receptors (TCRs) provide to T cells after interacting with antigens / major histocompatibility complexes (MHCs). OX40L is an important co-stimulatory molecule and can be induced to express on professional antigen presenting cells (APCs) such as B cells, dendritic cells (DCs) and macrophages under inflammatory conditions. OX40L and its binding partner OX40 regulate the production of cytokines from T cells, antigen presenting cells, NK cells and NKT cells. Non-limiting examples of other T cell co-stimulatory molecules that can be targeted include CD28, CD80, CTLA-4, PDL-1, CD86, ICOS, ICOS-L, PDL-2, CD27, CD70, CD30, CD30L, CD40L, CD40, GITR, GITRL, TIM-1, TIM-2, TIM-3 and TIM-4.
[0062] In some embodiments of any aspect, the extracellular recognition portion comprises, consists of, or consists essentially of an anti-OX40L antibody, an antibody reagent, or an antigen binding portion thereof. OX40L, also known as tumor necrosis factor ligand superfamily member 4, is a gene encoding a cytokine of the tumor necrosis factor ligand family that mediates adhesion of activated T cells to endothelial cells. The sequence of OX40L is known in the art for many species, including humans. For example, see NCBI database entry Gene ID No: 7292.
[0063] Antibodies and antibody reagents that specifically bind to OX40L are known in the art and are commercially available. For example, the following anti-OX40L antibodies are commercially available: Ab263910 [EPR23155-317] from Abcam; Ab76130[EP1168Y] was from Abcam; LS-B10561[362CT19.3.3] from LSBio; AB_2207272 / Cat.No.326307[11C3.1] from BioLegend; MAD10541[159403] from RnD Systems; MA5-37543 [362CT19.3.3] from Invitrogen; M02554[OTI5D8] from BoosterBio; sc-71768[2Q1716] from Santa Cruz Biotechnology; and AM01048PU-S[7D6] was from Origene.
[0064] In some embodiments, described herein is a CAR with an extracellular recognition portion comprising, consisting of, or consisting essentially of an OX40L antibody reagent, an OX40L antibody reagent comprising a light chain CDR encoded by a nucleic acid sequence of SEQ ID Nos 1-3 or a conservative substitution variant of such a nucleic acid sequence. In some embodiments, described herein is a CAR with an extracellular recognition portion comprising, consisting of, or consisting essentially of an OX40L antibody reagent, an OX40L antibody reagent comprising a heavy chain CDR encoded by a nucleic acid sequence of SEQ ID Nos 4-6 or a conservative substitution variant of such a nucleic acid sequence.
[0065] In some embodiments of any aspect, the extracellular recognition domain of the CAR described herein includes: light chain CDRs encoded by the nucleic acid sequence shown in SEQ ID NOs: 1-3 and heavy chain CDRs encoded by the nucleic acid sequence of SEQ ID NOs: 4-6, or SEQ ID NOs: 1-3 and SEQ ID NOs: 4-6 sequences at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical, maintaining the same function of the nucleic acid sequence. In some embodiments of any aspect, the CAR comprises at least one heavy chain or light chain complementary determining region (CDR) encoded by a nucleic acid selected from the group consisting of: (a) a light chain CDR1 having the nucleic acid sequence of SEQ ID NO: 1; (b) a light chain CDR2 having the nucleic acid sequence of SEQ ID NO: 2; (c) a light chain CDR3 having the nucleic acid sequence of SEQ ID NO: 3; (d) a heavy chain CDR1 having the nucleic acid sequence of SEQ ID NO: 4; (e) a heavy chain CDR2 having the nucleic acid sequence of SEQ ID NO: 5; and (f) a heavy chain CDR3 having the nucleic acid sequence of SEQ ID NO: 6.
[0066] SEQ ID NO 1: is a nucleic acid sequence encoding light chain CDR1:
[0067] SEQ ID NO 2: is a nucleic acid sequence encoding light chain CDR2:
[0068] SEQ ID NO 3: is a nucleic acid sequence encoding light chain CDR3:
[0069] SEQ ID NO 4: is a nucleic acid sequence encoding heavy chain CDR1:
[0070] SEQ ID NO 5: is a nucleic acid sequence encoding heavy chain CDR2:
[0071] SEQ ID NO 6: is a nucleic acid sequence encoding heavy chain CDR3:
[0072] In some embodiments, described herein are CARs with extracellular recognition portions, comprising, consisting of, or consisting essentially of an anti-OX40L antibody agent containing a light chain CDRs of SEQ ID Nos 7-9 or a conservative substitution variant of such sequences. In some embodiments, described herein are CARs with extracellular recognition portions, comprising, consisting of, or consisting essentially of an anti-OX40L antibody agent containing a heavy chain CDRs of SEQ ID Nos 10-12 or a conservative substitution variant of such nucleic acid sequences.
[0073] In some embodiments of any aspect, the extracellular recognition portion of the CAR described herein comprises: light chain CDRs having an amino acid sequence as shown in SEQ ID NOs: 7-9 and heavy chain CDRs having an amino acid sequence as shown in SEQ IDs 10-12, or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequences of SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12, and retains the same function. In some embodiments of any aspect, the CAR comprises at least one heavy chain or light chain complementary determining region (CDR) selected from the group consisting of: (g) a light chain CDR1 having the amino acid sequence of SEQ ID NO: 7; (h) a light chain CDR2 having the amino acid sequence of SEQ ID NO: 8; (i) a light chain CDR3 having the amino acid sequence of SEQ ID NO: 9; (j) a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 10; (k) a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 11; and (l) a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:12.
[0074] SEQ ID NO 7: is the amino acid sequence of light chain CDR1:
[0075] SEQ ID NO 8: is the amino acid sequence of light chain CDR2:
[0076] SEQ ID NO 9: is the amino acid sequence of light chain CDR3:
[0077] SEQ ID NO 10: is the amino acid sequence of heavy chain CDR1:
[0078] SEQ ID NO 11: is the amino acid sequence of heavy chain CDR2:
[0079] SEQ ID NO 12: is the amino acid sequence of heavy chain CDR3:
[0080] The VH domain and VL domain of the antibody can be connected by a peptide linker to form a VH / VL single-chain antigen-binding domain (e.g., as an scFv). As used herein, the term "linker" refers to a chemical or peptide structure that covalently connects two polypeptide parts. The length of the linker can be varied to change the ability of the connecting domain to form, for example, intramolecular or intermolecular dimers. For example, a bispecific antibody includes a short linker peptide between the VH and VL domains, typically 5 amino acids, which does not allow the VH and VL domains to pair to form an antigen-binding domain; expression of two different VH-VL constructs with such a short linker in a cell allows the VH domain of the first VH-VL polypeptide chain to dimerize with the VL domain of the second VH-VL polypeptide chain, and the corresponding VL domain of the first VH-VL polypeptide chain to dimerize with the VH domain of the second VH-VL polypeptide chain, thereby generating a bispecific construct. In contrast, when the VH and VL domains are separated by a longer peptide linker (usually 15-20 amino acids), the VH and VL domains on the same polypeptide chain can dimerize to form scFv.
[0081] In some embodiments of any aspect, the CAR described herein comprises a joint domain between the VL and VH domains of the extracellular recognition portion. In some embodiments of any aspect, the joint domain comprises, consists of, or consists essentially of a polypeptide encoded by SEQ ID NO: 13 or a polypeptide encoded by SEQ ID NO: 13 at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical.
[0082] In some embodiments of any aspect, the linker domain is encoded by the nucleic acid sequence shown in SEQ ID NO:13, or a nucleic acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of SEQ ID NO:13.
[0083] SEQ ID NO: 13 is the nucleic acid sequence encoding the CAR linker domain.
[0084] In addition to scFvs, non-antibody-based methods have also been used to direct CAR specificity, usually using ligand functional domains. As used herein, a "ligand functional domain" is a portion of a molecule that binds to another molecule. In some embodiments of any aspect, the polypeptides described herein may include cytokines, innate immune receptors, TNF receptors, growth factors, and structural proteins, which have been successfully used as CAR extracellular recognition portions. In some embodiments of any aspect, the natural ligand functional domains that can direct CAR specificity in the polypeptides described herein include NKp30, NKG2D, DNAM-1, CD27, CD16, GM-CSF, Adnectin, IL-13, IL-11, FSH, and T1E.
[0085] In some embodiments of any aspect, the CAR described herein further comprises a leader sequence on the N-terminus of the extracellular recognition portion. As used herein, the term "leader sequence" refers to an amino-terminal sequence comprising a signal peptide or consisting of a signal peptide. The signal peptide is generally composed of 13 to 36 fairly hydrophobic amino acids. Signal peptides have a common structure: a short, positively charged amino-terminal region (n region); a central hydrophobic region (h region); and a more polar carboxyl-terminal region (c region) comprising a site cut by a signal peptidase. On the ER luminal side, the signal peptide is cut off by a signal peptidase. After the successful folding of the nascent polypeptide by the ER-resident chaperones and folding enzymes, the protein is further guided to exit the ER. This process can be supported by the presence of an N-terminal pre-sequence.
[0086] In some embodiments of any aspect, the leader sequence encodes a CD8a signal peptide. In some embodiments, the leader sequence of the CAR described herein is encoded by: a nucleic acid sequence shown in SEQ ID NO: 14, or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 14, or a codon-optimized version of SEQ ID NO: 14. In some embodiments of any aspect, the leader sequence comprises, consists of, or consists essentially of a polypeptide encoded by SEQ ID NO:14, or a polypeptide that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the polypeptide encoded by SEQ ID NO:14.
[0087] SEQ ID NO: 14 is a nucleic acid sequence encoding a CAR leader sequence.
[0088] The CAR polypeptide described herein includes a transmembrane portion. The transmembrane portion is a structural component, generally comprising a hydrophobic alpha helix across the cell membrane. It anchors CAR to the plasma membrane, bridging the extracellular hinge and / or recognition portion with the intracellular signal transduction portion. This domain promotes the stability of the receptor as a whole. Transmembrane structures and sequences are well known in the art, for example, for any transmembrane protein with annotations in the PDB or NCBI database. Regarding the transmembrane portion, the CAR can be designed to include a transmembrane portion fused to the extracellular recognition of the CAR. In some embodiments of any aspect, a transmembrane portion naturally associated with one of the other portions in the CAR is used. In some cases, the transmembrane portion can be selected or modified by amino acid substitution to avoid binding of these portions to the transmembrane portion of the same or different surface membrane proteins, thereby minimizing the interaction with other members of the receptor complex.
[0089] In some embodiments of any aspect, the transmembrane portion may be derived from a natural or synthetic source. If the source is natural, the transmembrane portion may be any membrane-bound or transmembrane protein or a transmembrane portion derived therefrom. The transmembrane portion of the specific use of the CAR polypeptide described herein includes (i.e., including at least the following transmembrane region) T cell receptor α, β or ζ chain, CD28, CD23ζ, CD28, 4-1BB, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, the transmembrane portion may be synthetic, in which case it will mainly include hydrophobic residues such as leucine and valine. Preferably, a triplet of phenylalanine, tryptophan and valine is found at each end of the synthetic transmembrane portion. Optionally, a short oligopeptide or polypeptide linker preferably having a length between 2 and 10 amino acids may form a connection between the intracellular signaling portion and the transmembrane portion of the CAR. Glycine-serine doublets provide particularly suitable linkers. In some embodiments of any aspect, the transmembrane portion comprises the transmembrane portion of CD28. In some embodiments of any aspect, the transmembrane domain comprises the transmembrane portion of CD8.
[0090] The CAR may further include a hinge region between the extracellular recognition portion and the transmembrane portion. The term "hinge region" as used herein generally means any oligopeptide or polypeptide that plays a role in connecting the transmembrane portion to the extracellular recognition portion. In particular, the hinge region is used to provide greater flexibility and accessibility for the extracellular recognition portion. The hinge region may include up to 300 amino acids, preferably 10 to 100 amino acids, and most preferably 25 to 50 amino acids. The hinge region may be derived from all or part of a naturally occurring molecule, for example, all or part of the extracellular region of CD8, CD4 or CD28, or all or part of an antibody constant region. Alternatively, the hinge region may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or may be a fully synthetic hinge sequence.
[0091] In some embodiments of any aspect, the transmembrane portion and hinge domain of the CAR described herein include, consist of, or consist essentially of a polypeptide sequence encoded by: the nucleic acid sequence shown in SEQ ID NO: 15, or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 15, retaining the same function, or a codon-optimized version of SEQ ID NO: 15.
[0092] SEQ ID NO: 15 is the nucleic acid sequence encoding the hinge and transmembrane portion of CAR:
[0093] In some embodiments of any aspect, the CAR described herein comprises an intracellular signaling portion. As used herein, "intracellular signaling portion" refers to a polypeptide sequence comprising one or more TCR signaling domains, and when CAR is expressed in a cell, it will be displayed on the intracellular space of the cell membrane. After the antigen binds to the extracellular recognition portion, the CAR receptors gather together and transmit activation signals, and the intracellular signaling portion of the receptor continues signaling in the T cell. Normal T cell activation by TCR signaling depends on the phosphorylation of the immunoreceptor tyrosine activation motif (ITAMs) present in the intracellular domain of CD3ζ. In order to simulate this process, the intracellular domain of CD3ζ is generally used as a part of the intracellular signaling portion of CARs described herein. In some embodiments of any aspect, any domain containing ITAM can be used in the intracellular signaling portion of the CAR polypeptide described herein. Examples of ITAMs containing primary cytoplasmic signaling sequences (particularly useful in CAR polypeptides described herein) include those derived from TCR ζ (also referred to as ζ chain, CD3 ζ or CD247), FcR γ, FcR β, CD3 γ, CD3 δ, CD3 ε, CD5, CD22, CD79a, CD79b and CD66d. The cytoplasmic signaling molecules in CAR polypeptides may include CD3 ζ or a cytoplasmic signaling sequence derived from CD3 ζ.
[0094] In addition to CD3 signaling, co-stimulatory molecules also promote the persistence of T cells after activation. Therefore, the intracellular signaling portion of the CAR described herein may further include one or more co-signaling domains from co-stimulatory proteins. The participation of these co-signaling domains improves T cell proliferation, cytokine secretion, apoptosis resistance, and in vivo persistence. In some embodiments of any aspect, co-signaling domains from a variety of co-stimulatory molecules can be used for polypeptides described herein, including CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83, etc. The co-stimulatory domains of various TCR complex proteins are known in the art, for example, as annotated by NCBI database entries, including CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C and B7-H3. In several aspects, described herein are CAR polypeptides comprising at least one intracellular signaling portion.
[0095] In some embodiments of any aspect, the intracellular portion comprises a signaling domain of CD3ζ and a signaling domain of CD28. In some embodiments of any aspect, the intracellular portion comprises a signaling domain of CD3ζ and a signaling domain of 4-1BB. In some embodiments of any aspect, the intracellular domain comprises one or more co-signaling domains from a CD28 domain, a 4-1BB domain, an IL2Rα or IL2Rβ JAK3 / STAT3 composite docking site, and a TGFβ-RSMAD2 / 3 docking site.
[0096] In one embodiment of any aspect, the intracellular signaling portion is a signaling domain from a protein selected from the group consisting of: TCRC, FcRy, FcRp, CD3zeta, CD3y, CD35, CD3s, CD3C, CD22, CD79a, CD79b, CD66d, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, KD2C SLP76, TRIM, ZAP70 and 41BB.
[0097] In some embodiments of any aspect, the CAR polypeptide described herein comprises intracellular signaling domains of CD28 and CD3ζ, which are encoded by the nucleic acid sequence shown in SEQ ID NO: 16, or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 16, retaining the same function, or a codon-optimized version of SEQ ID NO: 16.
[0098] SEQ ID NO: 16 is a nucleic acid sequence encoding the intracellular signaling portion of the CAR encoding CD28 and CD3ζ:
[0099] In some embodiments of any aspect, the CAR polypeptide described herein comprises an intracellular signaling portion of 4-1BB and CD3ζ, the intracellular signaling portion being encoded by a nucleic acid sequence comprising SEQ ID NO: 17, or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 18, maintaining the same function, or a codon-optimized version of SEQ ID NO: 17.
[0100] SEQ ID NO: 17 is a nucleic acid sequence encoding the intracellular signaling portion of the CAR of 4-1BB and CD3ζ:
[0101] In several aspects, described herein are CAR polypeptides comprising at least one detectable marker. As used herein, the term "detectable marker" refers to a portion that, when attached to a CAR polypeptide, confers detectability to the polypeptide or another molecule bound to the polypeptide. In some embodiments of any aspect, the CAR polypeptide comprises a detectable marker and / or a detectable polypeptide. In some embodiments of any aspect, the CAR polypeptide comprises a detectable polypeptide C-terminus or a detectable marker of an intracellular signaling moiety.
[0102] In some embodiments of any aspect, fluorescent moieties can be used as detectable markers, and detectable markers also include, for example, isotopes, fluorescent proteins and peptides, enzymes, components of specific binding pairs, chromophores, affinity tags defined herein, antibodies, colloidal metals (i.e., colloidal gold), and quantum dots. Detectable markers can be directly or indirectly detectable. Directly detectable markers do not require additional reagents or substrates to generate a detectable signal. Examples include isotopes and fluorophores. Indirectly detectable markers require the presence or action of one or more cofactors or substrates. Examples include enzymes, such as β-galactosidase, which can be detected by generating a colored reaction product after cleavage of a substrate, such as the chromogen X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside); horseradish peroxidase, which can be detected by generating a colored reaction product in the presence of the substrate diaminobenzidine; and alkaline phosphatase, which can be detected by generating a colored reaction product in the presence of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate. Non-limiting examples of affinity tags include Strep tags, chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), FLAG tags, HA tags, Myc tags, poly (His) tags, and derivatives thereof. In some embodiments of any aspect, the detectable marker is selected from GFP, V5, HA1, Myc, VSV-G, HSV, FLAG, HIS, mCherry, AU1, and biotin.
[0103] In some embodiments of any aspect, the detectable marker may be located at any position within the CAR polypeptide described herein. In some embodiments of any aspect, the detectable marker is located between any portion of the CAR polypeptide described herein, but is not found within a functional domain or portion, or does not destroy the function of a domain or portion. In some embodiments of any aspect, the detectable marker is located at the C-terminus of the polypeptide. This marker can be used to detect intracellular expression of CAR polypeptides. In some embodiments of any aspect, the detectable marker at the C-terminus of the polypeptide includes NeonGreen or another marker described herein.
[0104] In some embodiments of any aspect, the detectable marker of the CAR polypeptide described herein is encoded by a nucleic acid sequence comprising SEQ ID NOs: 18, or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to one of SEQ ID NOs: 18, retaining the same function, or a codon-optimized version of one of SEQ ID NOs: 18.
[0105] SEQ ID NO: 18 is a nucleic acid sequence encoding a CAR NeonGreen detectable marker:
[0106] In some embodiments of any aspect, the CAR polypeptides described herein, in particular the CAR polypeptides administered to a subject or the CAR polypeptides as part of a pharmaceutical composition, do not include a detectable marker of immunogenicity. In some embodiments of any aspect, the CAR polypeptides described herein do not include GFP, mCherry, HA1 or any other immunogenic marker.
[0107] In some embodiments of any aspect, CAR further includes a cleavage site between the intracellular signaling moiety and the detectable marker. In some embodiments of any aspect, the cleavage site is a short amino acid sequence (e.g., a peptide of about 18-22aa length) that can catalyze its own cleavage. In some embodiments of any aspect, the cleavage site belongs to the 2A peptide family. Non-limiting examples of 2A peptides include P2A, E2A, F2A, and T2A. F2A is derived from foot-and-mouth disease virus 18, E2A is derived from equine rhinitis A virus, P2A is derived from porcine teschovirus-1 2A, and T2A is derived from thosea asigna virus 2A. The cleavage sites of these 2A peptides are known in the art. In some embodiments of any aspect, the N-terminus of the 2A peptide comprises the sequence "GSG" (Gly-Ser-Gly). In some embodiments of any aspect, the N-terminus of the 2A peptide does not comprise the sequence "GSG" (Gly-Ser-Gly).
[0108] 2A peptide-mediated cleavage begins after protein translation. Cleavage is triggered by the break of the peptide bond between proline (P) and glycine (G) in the C-terminus of the 2A peptide. The molecular mechanism of 2A peptide-mediated cleavage involves ribosomal "jumping" of glycyl-prolyl peptide bond formation, rather than true proteolytic cleavage. Different 2A peptides have different self-cleavage efficiencies, with P2A being the most efficient and F2A being the least efficient. Therefore, up to 50% of F2A-linked proteins can remain in the cell as uncut proteins.
[0109] In some embodiments of any aspect, the cleavage site of the CAR described herein is encoded by a nucleic acid sequence shown in SEQ ID NO: 19, or a nucleic acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to one of SEQ ID NOs: 19, maintaining the same function, or a codon-optimized version of one of SEQ ID NOs: 19. In some embodiments of any aspect, the cleavage site comprises, consists of, or consists essentially of a polypeptide encoded by SEQ ID NO:2, or a polypeptide that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the polypeptide encoded by SEQ ID NO:2.
[0110] SEQ ID NO: 19 is the nucleic acid sequence encoding the CAR cleavage site.
[0111] In some embodiments of any aspect, T cell as described herein or T cell group include regulatory T cells (Tregs), are composed of Tregs or are substantially composed of Tregs. As used herein, "regulatory T cells" or "Treg" refer to those T cells (lymphocytes) with immunomodulatory properties and the ability to suppress the effector functions and / or proliferation of other T cell groups. As described below, many cell surface molecules are used to characterize and define Treg cells. Regulatory T cells or Treg cells play an important role in maintaining immune tolerance by suppressing the effect of autoreactive effector cells, and have been shown to be involved in the development of preventing autoimmune reactions to a great extent.
[0112] In some embodiments of any aspect, the Treg cell may be a T cell expressing one or more markers selected from the group consisting of CTLA4, PDL1, FOXP3, LAP, GARP, CD25, CD4, and CD27. In some embodiments of any aspect, the Treg cell may be a T cell expressing a detectable level of one or more markers selected from the group consisting of CTLA4, PDL1, FOXP3, LAP, GARP, CD25, CD4, and CD27. In some embodiments of any aspect, the Treg cell may be a T cell that is positive for one or more markers selected from the group consisting of CTLA4, PDL1, FOXP3, LAP, GARP, CD25, CD4, and CD27. In some embodiments of any aspect, the Treg cell may be a CD8- (e.g., NCBI Gene ID: 925) CD4+ (e.g., NCBI Gene ID: 920) CD3+ cell. In some embodiments of any aspect, the Treg cell expresses Foxp3. In some embodiments of any of the aspects, the Treg cells express CD4 and CD25.
[0113] "X+" (where "X" is a cell surface marker) indicates that the marker is present in the indicated cells, while "X-" indicates that the marker is not present. One skilled in the art will be able to assess the molecules present on cells using standard techniques, such as using immunofluorescence to detect commercially available antibodies that bind to the marker molecule. Such designators are often used when sorting or identifying cells by FACS, where gates can be established to separate cells based on the expression level of the marker.
[0114] In one embodiment, the method for preparing the engineered cells described herein includes obtaining a cell population and enriching CD25+T regulatory cells, for example, by using an antibody specific for CD25. The method of enriching CD25+T regulatory cells from a cell population is obvious to those skilled in the art, and may include the use of methods such as FACS or affinity purification. In some embodiments, the group of Treg-enriched cells includes less than 30%, 20%, 10%, 5% or less non-Treg cells. In some embodiments, the vector encoding CAR described herein is transfected into Treg-enriched cells. Treg cells (e.g., Treg-enriched cells) expressing CAR can be used to induce tolerance to antigens targeted or specifically bound by CAR.
[0115] CAR-T cell therapy uses T cells engineered with CARs for treatment. The premise of CAR-T immunotherapy is to modify T cells to recognize specific molecules or cells so that they can be more effectively targeted, blocked, or destroyed. The T cells are harvested, genetically altered, and then the resulting CAR-T cells are infused into the patient to treat them. CAR-T cells can be derived from T cells in the patient's own blood (autologous), or from T cells from other healthy donors (allogeneic). Once isolated, these T cells are genetically engineered to express a specific CAR, which programs them to target the antigen.
[0116] Further discussion of CARs can be found in, e.g., Maus et al., Blood, 2014, 123:2624-35; Reardon et al., Neuro-Oncology, 2014, 16:1441-1458; Hoyos et al., Haematologica, 2012, 97:1622; Byrd et al., J Clin Oncol, 2014, 32:3039-47; Maher et al., Cancer Res, 2009, 69:4559-4562; and Tamada et al., Clin Cancer Res, 2012, 18:6436-6445; each of which is incorporated herein by reference in its entirety.
[0117] In one aspect of any embodiment, described herein is a nucleic acid molecule encoding a CAR as described herein. In one aspect of any embodiment, described herein is a vector, e.g., an expression vector, comprising a nucleic acid molecule encoding a CAR as described herein.
[0118] In some embodiments of any embodiment, the vector described herein is an expression vector or plasmid, for example, a recombinant vector or a plasmid. As used herein, the term "vector" refers to a polynucleotide sequence suitable for transferring a transgene into a host cell. The term "vector" includes plasmids, minichromosomes, bacteriophages, naked DNA, etc. See, for example, U.S. Patent Nos. 4,980,285, 5,631,150, 5,707,828, 5,759,828, 5,888,783 and 5,919,670, and Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press (1989). One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop in which additional DNA fragments are connected. Another type of vector is a viral vector, in which additional DNA fragments are connected to a viral genome. Some vectors can replicate autonomously in the host cell into which they are introduced (for example, bacterial vectors and episomal mammalian vectors with bacterial replication origins). In addition, certain vectors are capable of directing the expression of genes operably linked thereto. Such vectors are referred to herein as "expression vectors". In general, expression vectors useful in recombinant DNA technology are usually in the form of plasmids. In this specification, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used form of vectors. However, the present invention is intended to include other forms of expression vectors that serve equivalent functions, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses).
[0119] A cloning vector is a vector capable of autonomous replication or integration into the host cell genome, and is further characterized by one or more endonuclease restriction sites, at which the vector can be cut in a determined manner, and a desired DNA sequence can be connected thereto, so that the new recombinant vector retains its ability to replicate in the host cell. In the case of a plasmid, as the number of copies of the plasmid increases in the host cell (such as a host bacterium), the replication of the desired sequence can occur multiple times, or before the host reproduces by mitosis, each host only replicates the desired sequence once. In the case of a phage, replication can occur actively during the lytic phase, or can occur passively during the lysogenic phase.
[0120] Expression vector is a vector that can insert the desired DNA sequence by restriction and connection, so that it can be operably connected to the regulatory sequence and can be expressed as RNA transcript. The vector may further contain one or more marker sequences, which are suitable for identifying cells that have been transformed or untransformed or transformed or transfected by the vector. Markers include genes that encode, for example, increase or decrease the resistance or sensitivity of proteins to antibiotics or other compounds, genes (for example, beta-galactosidase, luciferase or alkaline phosphatase) encoding enzymes whose activity can be detected by standard assays known in the art, and genes (for example, green fluorescent protein) that affect the phenotype of cells, hosts, bacterium colonies or plaques that are transformed or transfected. In some embodiments, the vector used herein can autonomously replicate and express the structural gene products present in the DNA fragments that they are operably connected.
[0121] As used herein, a coding sequence and a regulatory sequence are said to be "operably" linked when they are covalently linked in a manner that places the expression or transcription of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if it is desired that the coding sequence be translated into a functional protein, if induction of a promoter in the 5' regulatory sequence results in transcription of the coding sequence, and if the nature of the connection between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region to direct transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into protein. Thus, a promoter region will be operably linked to a coding sequence if the promoter region is able to influence the transcription of the DNA sequence so that the resulting transcript can be translated into the desired protein or polypeptide.
[0122] When the nucleic acid molecules encoding any polypeptide described herein are expressed in cells, a variety of transcriptional control sequences (e.g., promoter / enhancer sequences) may be used to direct their expression. The promoter may be a natural promoter, i.e., a promoter of a gene in its endogenous environment, which provides normal regulation of gene expression. In some embodiments, the promoter may be constitutive, i.e., the promoter is unregulated, allowing continuous transcription of its associated gene. A variety of conditional promoters may also be used, such as promoters controlled by the presence or absence of a molecule.
[0123] The precise nature of the regulatory sequences required for gene expression may vary between species or cell types, but may generally include (as needed) 5' non-transcribed and 5' non-translated sequences involved in transcription initiation and translation initiation, respectively, such as a TATA box, a capping sequence, a CAAT sequence, and the like. In particular, such 5' non-transcribed regulatory sequences will include a promoter region including a promoter sequence for transcriptional control of an operably linked gene. The regulatory sequence may also include an enhancer sequence or an upstream activator sequence as desired. The vectors of the present invention may optionally include a 5' leader or signal sequence. The selection and design of suitable vectors are within the ability and discretion of those of ordinary skill in the art.
[0124] In some embodiments of any aspect, the promoter is a eukaryotic or human constitutive promoter, including but not limited to FoxP3 promoter, Fox P3 and IKZF2 / Helios hybrid promoter, MND promoter, etc. In some embodiments of any aspect, the vector comprises a human FoxP3 promoter (e.g., SEQ ID NO: 20), which is a constitutive promoter of human origin that can be used to drive gene expression in regulatory T cells in in vitro and in vivo environments.
[0125] In some embodiments of any aspect, the FoxP3 promoter of the CAR described herein is encoded by the nucleic acid sequence shown in SEQ ID NO: 20, or a nucleic acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 20, maintaining the same function, or a codon-optimized version of SEQ ID NO: 20.
[0126] SEQ ID NO: 20 is the nucleic acid sequence encoding the FoxP3 promoter.
[0127] In some embodiments of any aspect, the promoter is a promoter provided by Accession No. MK012431, e.g., nucleotides 4650-6041 and 7338-8213 of Accession No. MK012431, a version of which was obtained on February 28, 2023.
[0128] Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. For example, the cell is genetically engineered by introducing heterologous DNA (RNA) into the cell. The heterologous DNA (RNA) is placed under the operable control of transcriptional elements to allow expression of the heterologous DNA in the host cell.
[0129] In some embodiments, the vector includes a selectable marker, for example, for selectively amplifying the vector in bacteria. Non-limiting examples of selectable marker genes for use in bacteria include antibiotic resistance genes that confer resistance to ampicillin, tetracycline, and kanamycin. The tetracycline (tet) and ampicillin (amp) resistance marker genes can be obtained from any of a variety of commercially available vectors, including pBR322 (available from New England BioLabs, Beverly, Mass., cat. no. 303-3s). The tet coding sequence is contained within nucleotides 86-476, and the amp gene is contained within nucleotides 3295-4155. The nucleotide sequence of the kanamycin (kan) gene can be obtained from the vector pACYC177, which is from New England BioLabs, Cat no. 401-L, GenBank accession number X06402.
[0130] In some embodiments of any of the aspects, one or more nucleic acids encoding a CAR as described herein can be integrated into the genome of a cell.
[0131] In some embodiments of any aspect, immune cells (e.g., Treg) comprising CAR polypeptides can be used to treat inflammatory conditions or autoimmune diseases. In some embodiments, immune cells (e.g., T cells) containing CAR polypeptides (for autoimmune disease-specific antigens) can be used to treat autoimmune diseases. "Autoimmune disease" refers to a class of diseases in which the subject's own antibodies react with host tissues, or wherein immune effector T cells are autoreactive to endogenous self-peptides and cause tissue destruction. Therefore, the immune response is generated for the subject's own antigens (referred to as self-antigens). "Self-antigens" used herein refer to antigens of normal host tissues. Normal host tissues do not include neoplastic cells.
[0132] Autoantigens used herein are endogenous proteins or fragments thereof that trigger such pathogenic immune responses. Autoantigens can be any substance or part thereof normally found in mammals, which become the main (or main) target of immune system attack in autoimmune diseases. The term also includes antigenic substances that induce the disease with autoimmune disease characteristics when given to mammals. In addition, the term includes digestive subclasses consisting essentially of immunodominant epitope regions or immunodominant epitopes of autoantigens. In induced autoimmune disorders, immunodominant epitopes or regions are fragments of autoantigens, which can be used to replace whole autoantigens to induce disease. In humans suffering from autoimmune diseases, immunodominant epitopes or regions are fragments of antigens specific to tissues or organs that are attacked by autoimmunity, and are recognized by a considerable percentage (e.g., most but not necessarily an absolute majority) of autoimmune attacking T cells.
[0133] Autoantigens known to be associated with autoimmune diseases include myelin proteins in demyelinating diseases (e.g., multiple sclerosis and experimental autoimmune myelitis), collagen and rheumatoid arthritis, insulin, proinsulin, glutamic acid decarboxylase 65 (GAD65), and islet cell antigens (ICA512, ICA12) in insulin-dependent diabetes mellitus.
[0134] A common feature in many autoimmune-related diseases and inflammatory conditions is the involvement of proinflammatory CD4+T cells. These T cells are responsible for the release of inflammatory Th1-type cytokines. Cytokines characterized by Th1 type include interleukin 2 (IL-2), gamma-interferon, TNFα and IL-12. The action of this proinflammatory cytokine stimulates the immune response, leading to the destruction of autologous tissue in many cases. The cytokines associated with suppressing T cell responses are Th2 type and include IL-10, IL-4 and TGF-β. It has been found that Th1 and Th2 type T cells can respond to immunogens using the same antigen receptors; a stimulatory response is produced in the former, while a suppressive response is produced in the latter.
[0135] Described herein is a method for treating an autoimmune disease, the method comprising administering an effective amount of a CAR or CAR-T composition to a patient in need thereof. In some embodiments of any of the methods described herein, the autoimmune disorder is selected from the group consisting of thyroiditis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, celiac disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, and Raynaud's phenomenon, Goodpasture's disease, arthritis (rheumatoid arthritis such as acute arthritis, chronic rheumatoid arthritis, gout or gouty arthritis, acute gouty arthritis, acute immune arthritis, chronic inflammatory arthritis, degenerative arthritis, type II collagen-induced arthritis, infectious arthritis, Lyme arthritis, hyperplastic arthritis, psoriatic arthritis, Still's disease, spondyloarthritis and juvenile onset rheumatoid arthritis, chronic progressive arthritis, deforming arthritis, primary chronic polyarthritis, reactive arthritis and ankylosing spondylitis), inflammation hyperproliferative skin diseases, psoriasis such as plaque psoriasis, guttate psoriasis, pustular psoriasis and nail psoriasis, atopy (including atopic diseases such as hay fever and Job's syndrome), dermatitis (including contact dermatitis, chronic contact dermatitis, exfoliative dermatitis, allergic dermatitis, allergic contact dermatitis, dermatitis herpetiformis, nummular dermatitis, seborrheic dermatitis, nonspecific dermatitis, primary irritant contact dermatitis and atopic dermatitis), X-linked hyper-IgM syndrome, allergic intraocular inflammatory diseases, urticaria (such as chronic allergic urticaria and chronic idiopathic urticaria, including chronic autoimmune urticaria), myositis, polymyositis / dermatomyositis, juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma (including systemic sclerosis), sclerosis (such as systemic sclerosis, multiple sclerosis (MS) such as spino-optical MS) MS), primary progressive MS (PPMS) and relapsing-remitting MS (RRMS), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, disseminated sclerosis, ataxia), neuromyelitis optica (NMO), inflammatory bowel disease (IBD) (e.g., Crohn's disease, autoimmune-mediated gastrointestinal diseases, colitis such as ulcerative colitis, ulcerative colitis, microscopic colitis, collagenous colitis, polyposis colitis, necrotizing enterocolitis, and transmural colitis, and autoimmune inflammatory bowel disease), intestinal inflammation, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, respiratory distress syndrome (including adult or acute respiratory distress syndrome (ARDS)), meningitis, inflammation of all or part of the uvea, iritis, choroiditis, autoimmune blood disease, rheumatoid spondylitis, rheumatoid synovitis, hereditary angioedema, cranial nerve damage such as in meningitis, herpes gestationis, pemphigoid gestationis, scrotal pruritus, autoimmune premature ovarian failure,Sudden hearing loss due to autoimmune disorders, IgE-mediated diseases such as anaphylaxis and allergic and atopic rhinitis, encephalitis such as Rasmussen encephalitis, limbic encephalitis and / or brainstem encephalitis, uveitis (such as anterior uveitis, acute anterior uveitis, granulomatous uveitis, non-granulomatous uveitis, lens antigenic uveitis, posterior uveitis or autoimmune uveitis), glomerulonephritis (GN) with or without nephrotic syndrome (such as chronic or acute glomerulonephritis, such as primary GN, immune-mediated GN, membranous GN (membranous nephropathy), idiopathic membranous GN or idiopathic membranous nephropathy, membranous GN or membranoproliferative GN (MPGN) including type I and II, and rapidly progressive GN) glomerular nephritis, proliferative nephritis), autoimmune polyglandular endocrine failure, balanitis (including localized plasma cell balanitis, balanitis), erythema annulare centrifugal, erythema dyschromatoticum perseverant, erythema multiforme, granuloma annulare, lichen lustrous, lichen sclerosus atrophicus, lichen simplex chronicus, lichen spinulosus, lichen planus, lamellar ichthyosis, epidermolytic hyperkeratosis, precancerous keratosis, pyoderma gangrenosum, allergic conditions and responses, allergic reactions, eczema including allergic or atopic eczema, seborrheic eczema, dry eczema, dyshidrotic eczema and palmoplantar vesicular eruption, asthma such as bronchial asthma, bronchial asthma and autoimmune asthma, conditions involving T cell infiltration and chronic inflammatory response, immunity to exogenous antigens Reactions such as fetal ABO blood type during pregnancy, chronic inflammatory lung disease, autoimmune myocarditis, leukocyte adhesion defects, lupus (including lupus nephritis, lupus encephalitis, pediatric lupus, nonrenal lupus, extrarenal lupus, discoid lupus and discoid lupus erythematosus, alopecia, systemic lupus erythematosus (SLE) such as cutaneous SLE or subacute cutaneous SLE, neonatal lupus syndrome (NLE), and disseminated lupus erythematosus), juvenile-onset (type I) diabetes (including pediatric insulin-dependent diabetes mellitus (IDDM)), adult-onset diabetes (type II diabetes), autoimmune diabetes, idiopathic diabetes insipidus, diabetic retinopathy, diabetic nephropathy, diabetic aortic disorder, and cytokines Immune responses related to acute and delayed hypersensitivity reactions mediated by T lymphocytes, sarcoidosis, granulomatous diseases including lymphomatoid granulomatosis, Wegener's granulomatosis, agranulocytosis, vasculitic diseases including vasculitis, large vessel vasculitis (including polymyalgia rheumatica and giant cell arteritis (Takayasu's arteritis)), medium vessel vasculitis (including Kawasaki disease and polyarteritis nodosa / periarteritis nodosa), microscopic polyarteritis, immune vasculitis, CNS vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, necrotizing vasculitis such as systemic necrotizing vasculitis, ANCA-associated vasculitis (such as Churg-Strauss vasculitis or syndrome (CSS) and ANCA-associated small vessel vasculitis), temporal arteritis,Autoimmune aplastic anemia, Coombs-positive anemia, Diamond Blackfan anemia, hemolytic anemia or immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia (pernicious anemia), Addison's disease, pure red cell anemia or aplasia (PRCA), factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocytopenia, CNS inflammatory diseases, multi-organ injury syndromes such as those secondary to sepsis, trauma, or hemorrhage, antigen-antibody complex-mediated diseases, anti-glomerular basement membrane disease, antiphospholipid antibody syndrome, allergic neuritis, Behcet's disease / syndrome , Castleman syndrome, Goodpasture syndrome, Raynaud's syndrome, Sjögren's syndrome, Stevens-Johnson syndrome, pemphigoid such as pemphigoid fumigatus and cutaneous pemphigoid, pemphigus (including pemphigus vulgaris, pemphigus foliaceus, mucous membrane pemphigoid, and pemphigus erythematosus), autoimmune polyendocrinopathy, Reiter disease or syndrome, immune complex disease such as immune complex nephritis, antibody-mediated nephritis, polyneuropathy, chronic neuropathies such as IgM polyneuropathy or IgM-mediated neuropathy, autoimmune or immune-mediated thrombocytopenia such as idiopathic ITP (ITP) including chronic or acute ITP, scleritis such as idiopathic keratoscleritis, episcleritis, autoimmune diseases of the testicles and ovaries including autoimmune orchitis and oophoritis, primary hypothyroidism, hypoparathyroidism, autoimmune endocrine diseases including thyroiditis such as autoimmune thyroiditis, Hashimoto's disease, chronic thyroiditis (Hashimoto's thyroiditis) or subacute thyroiditis, idiopathic hypothyroidism, polyglandular syndromes such as autoimmune polyglandular syndrome (or polyglandular endocrine syndrome), paraneoplastic syndromes (including paraneoplastic syndromes of the nervous system such as Lambert- Eaton myasthenic syndrome or Eaton-Lambert syndrome, stiff man or stiff person syndrome), encephalomyelitis such as allergic encephalomyelitis or allergic encephalomyelitis and experimental allergic encephalomyelitis (EAE), myasthenia gravis such as thymoma-associated myasthenia gravis, cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus-myoclonus syndrome (OMS) and sensory neuropathy, multifocal motor neuropathy, Sheehan syndrome, autoimmune hepatitis, lupus hepatitis, giant cell hepatitis, autoimmune chronic active hepatitis, lymphocytic interstitial pneumonia (LIP), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barré syndrome, Berger's disease (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, acute febrile neutrophilic dermatosis, subcorneal pustular dermatosis, transient acantholytic dermatosis,Cirrhosis of the liver such as primary biliary cirrhosis and pulmonary cirrhosis, autoimmune enteropathy syndrome, celiac disease or celiac disease, celiac stomatitis (gluten enteropathy), refractory stomatitis, idiopathic stomatitis, cryoglobulinemia, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), coronary artery disease, autoimmune ear diseases such as autoimmune inner ear disease (AIED), autoimmune hearing loss, polychondritis such as relapsing or refractory polychondritis, pulmonary alveolar proteinosis, Cogan syndrome / nonsyphilitic interstitial keratitis, Bell's palsy, Sweet's disease / syndrome, autoimmune rosacea, pain associated with herpes zoster, amyloidosis, noncancerous lymphocytosis, primary lymphocytosis (including monoclonal B-cell lymphocytosis (e.g., benign monoclonal gammopathy and monoclonal gammopathy of undetermined significance, MGUS)), peripheral neuropathy, paraneoplastic syndromes, channelopathies including those of the CNS, autism, inflammatory myopathies, focal or segmental glomerulosclerosis (FSGS), endocrine eye diseases, uveoretinitis, chorioretinitis, autoimmune liver disease, fibromyalgia, multiple endocrine failure, Schmidt syndrome, adrenalitis, gastric atrophy, Alzheimer's disease, demyelinating diseases such as autoimmune demyelinating diseases and chronic inflammatory demyelinating polyneuropathy, Dressler syndrome, alopecia areata, alopecia totalis, CREST syndrome (calcification, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility ( such as due to antisperm antibodies), mixed connective tissue disease, Chagas disease, rheumatic fever, recurrent abortion, farmer's lung, erythema multiforme, postcardiotomy syndrome, Cushing's syndrome, bird-swallowed lung, allergic granulomatous vasculitis, benign lymphocytic vasculitis, Alport syndrome, alveolitis such as allergic alveolitis and fibrosing alveolitis, interstitial lung disease, transfusion reaction, Sampter's syndrome, Caplan syndrome, endocarditis, endomyocardial fibrosis, diffuse interstitial pulmonary fibrosis, interstitial pulmonary fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, endophthalmitis, erythema perstans, fetal hemolytic disease, eosinophilic fasciitis, Shulman syndrome, Felty syndrome, cyclitis such as chronic cyclitis, heterochromic cyclitis, iridocyclitis (acute or chronic) or Fuch's cyclitis, Henoch-Schonlein purpura, SCID, sepsis, endotoxemia, postvaccination syndrome, Evan's syndrome, autoimmune gonadal failure, Sydenham chorea, poststreptococcal nephritis, thromboangiitis obliterans, thyrotoxicosis, tabes dorsalis, choroiditis, giant cell polymyalgia, chronic hypersensitivity pneumonitis, keratoconjunctivitis sicca, idiopathic nephrotic syndrome, minimal change nephropathy, benign familial and ischemic reperfusion injury,Reperfusion of transplanted organs, autoimmune diseases of the retina, aphthous ulcers, aphthous stomatitis, atherosclerotic disease, azoospermia, autoimmune hemolysis, Boeck's disease, allergic enteritis, erythema nodosum leprosum, idiopathic facial nerve palsy, chronic fatigue syndrome, rheumatic fever, Hamman-Rich disease, sensorineural hearing loss, regional ileitis, leukopenia, transverse myelitis, primary idiopathic myxedema, sympathetic ophthalmia symphatica), acute polyradiculitis, pyoderma gangrenosum, acquired splenic atrophy, vitiligo, toxic shock syndrome, disorders involving T-cell infiltration, leukocyte adhesion defects, immune responses associated with acute and delayed hypersensitivity reactions mediated by cytokines and T lymphocytes, diseases involving leukocyte infiltration, multiple organ injury syndrome, antigen-antibody complex-mediated diseases, anti-glomerular basement membrane disease, allergic neuritis, autoimmune polyendocrine disease, oophoritis, primary myxedema, autoimmune atrophic gastritis, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyendocrine failure, autoimmune polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), myocarditis, nephrotic syndrome, primary sclerosing cholangitis, acute or chronic sinusitis, ethmoid sinusitis, frontal sinusitis, maxillary sinusitis, or sphenoid sinusitis , Eosinophil-related diseases such as eosinophilia, pulmonary infiltrative eosinophilia, eosinophilia-myalgia syndrome, Loffler syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia, granulomas containing eosinophils, seronegative spondyloarthropathies, polyendocrine autoimmune diseases, sclerosing cholangitis, sclerosis, episclerosis, Bruton's syndrome, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia-telangiectasia syndrome, vasodilation, autoimmune diseases associated with collagen diseases, rheumatism, allergic hypersensitivity disorders, glomerulonephritis, reperfusion injury, ischemic reperfusion disorders, lymphomatous tracheobronchitis, inflammatory skin diseases, skin diseases with acute inflammatory components, and autoimmune uveoretinitis (AUR). ,
[0136] Described herein are methods of treating an autoimmune disorder or an inflammatory disorder, the method comprising administering an effective amount of a CAR or CAR-T composition to a patient in need thereof. In some embodiments of any of the methods described herein, the autoimmune disorder or inflammatory disorder is selected from the group consisting of allogeneic transplant rejection, xenograft rejection, and graft-versus-host disease.
[0137] In some embodiments, the methods described herein relate to the treatment or prevention of transplant rejection or GVHD in a subject with tissue transplantation, organ transplantation or hematopoietic stem cell transplantation (HCT) performed with one or more compositions, CARs or cells as described herein. In some embodiments of any aspect, transplant rejection is allogeneic transplant rejection or xenograft rejection. In another embodiment, the methods described herein relate to the treatment or prevention of graft-versus-host disease (GVHD) in a subject with tissue transplantation, organ transplantation or HCT performed with one or more compositions, CARs or cells as described herein.
[0138] As used herein, "GVHD" refers to a disease characterized by an active process in which donor cells attack the recipient's own cells. GVHD may develop soon after transplantation, such as within weeks or months (acute GVHD), or may occur later after transplantation, such as at least 3-6 months later (chronic GVHD). Symptoms of acute GVHD include, but are not limited to, rash or blisters, abdominal pain or discomfort, diarrhea, jaundice, and edema. Symptoms of chronic GVHD include, but are not limited to, changes in skin or nail texture, hair loss or thinning of hair, muscle pain or weakness, blurred vision, mouth ulcers, shortness of breath, persistent cough, abdominal pain or discomfort, and diarrhea.
[0139] A skilled clinician can identify whether a subject has or is at risk of developing GVHD. Diagnostic tests for identifying subjects with GVHD are known in the art and vary depending on the type of transplant the subject receives. For example, diagnosis of GVHD is performed by physical examination for signs and symptoms of GVHD known in the art, serological tests for dysfunction of the liver, gallbladder, kidneys, and hematopoietic cells, histological analysis of biopsies obtained from affected organs, and radiographic imaging of affected organs. In one embodiment, the method further comprises administering at least a second therapeutic agent. In one embodiment, the composition, CAR, or cell described herein is administered with abatacept. or Belatacept Administered in combination. Abatacept and Belatacept were developed by Bristol-Myers Squibb and are fusion proteins consisting of the Fc region of immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. Abatacept is currently FDA-approved for the treatment of rheumatoid arthritis. Belatacept differs from Abatacept only by two amino acids and is an immunosuppressant designed to prevent rejection after kidney transplantation.
[0140] In some embodiments of any aspect, the transplant is a vascularized composite allograft (VCA). In another embodiment, the transplant is any type of transplant procedure, such as any heart transplant, any lung transplant, any liver transplant, any pancreas transplant, any corneal transplant, any tracheal transplant, any kidney transplant, any skin transplant, or any autologous transplant (e.g., tissue transplant). In one embodiment of any aspect, the transplant is any allograft or xenograft. A skilled practitioner can perform the transplant or identify a subject that has undergone a transplant using standard procedural protocols.
[0141] The compositions and methods described herein may be administered to a subject to treat or prevent autoimmune diseases, inflammatory conditions, or transplant rejection. In certain embodiments, the methods described herein include administering to a subject an effective amount of a composition, CAR, or cell as described herein to reduce the symptoms of inflammatory conditions, autoimmune diseases, or transplant rejection. "Reducing the symptoms of inflammatory conditions, autoimmune diseases, or transplant rejection" as used herein is to alleviate any condition or symptom associated with inflammatory conditions, autoimmune diseases, or transplant rejection. Compared to an equivalent untreated control, as measured by any standard technique, this reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more. A variety of means for administering the compositions described herein to a subject are known to those skilled in the art. These methods may include, but are not limited to, oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), lung, skin, topical, injection, or intratumoral administration. Administration may be local or systemic.
[0142] It is contemplated herein that the administration of the composition can be carried out in any convenient manner, including aerosol inhalation, injection, intake, blood transfusion, implantation or transplantation. In a preferred embodiment, the composition is administered parenterally. The phrases "parenteral administration" and "parenteral administration" used herein refer to the mode of administration except intestinal and local administration, usually by injection, and include but are not limited to intravascular, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intratumoral, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. In one embodiment, it is contemplated herein that the composition is administered to the subject by direct injection into a tumor, lymph node or infection site.
[0143] Generally, it can be considered that the pharmaceutical composition comprising the cells described herein (eg, T cells or CAR cells) can be administered at a dosage of 1 to 10 mg / kg body weight. 10 The dosage of cells is preferably 10 per kg body weight. 3 Up to 10 8cells, including all integer values within these ranges. The number of cells will depend on the end use of the composition and the type of cells contained therein. For the uses described herein, the cells are typically in a volume of 1 L or less, perhaps 500 mL or less, or even 250 mL or 100 mL or less. Thus, the desired cell density is typically greater than 10 6 cells / mL and usually greater than 10 7 cells / mL, usually 10 8 Clinically relevant numbers of immune cells can be distributed into multiple infusions, accumulating to equal or exceed 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 or 10 12 In certain aspects of the invention, particularly because all infused cells will be redirected to a specific target antigen, a smaller number of cells may be administered, ranging from 10 6 cells / kg (10 per patient 6 -10 11 Cells). The cell composition expressing CAR can be administered multiple times at doses within these ranges. The cells can be allogeneic, syngeneic, xenogeneic or autologous for the patient being treated. If desired, treatment may also include administering mitogens (e.g., PHA) or lymphokines, cytokines and / or chemokines (e.g., IFN-γ, IL-2, IL-12, TNF-α, IL-18 and TNF-β, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1α, etc.) as described herein to enhance the induction of an immune response. In certain embodiments, the dosage may be from about 1×102 cells / kg body weight to about 1×10 10 In some embodiments, the dose may be about 1×10 5 cells / kg body weight is about 1×10 8 In some embodiments, the dose may be about 1×10 6 cells / kg body weight is about 1×10 7 cells / kg body weight. In some embodiments, the dose can be 1×10 6 In some embodiments, the dosage of cells can be repeated, for example, once, twice or more. In some embodiments, the dosage of cells can be administered daily, weekly or monthly.
[0144] The dosage range of the agent described herein (eg, CAR, cell or composition) depends on the efficacy and covers an amount large enough to produce the desired effect (eg, preventing transplant rejection, reducing inflammation, etc.). The dosage should not be too large to cause unacceptable adverse side effects. In general, the dosage will vary with the patient's age, condition and gender, and can be determined by a person skilled in the art. Individual doctors can also adjust the dosage appropriately when any complications occur. In some embodiments, the dosage range is 0.001 mg / kg body weight to 0.5 mg / kg body weight. In some embodiments, the dosage range is 5 μg / kg body weight to 100 μg / kg body weight. Alternatively, the dosage range can be titrated to maintain serum levels between 1 μg / mL and 1000 μg / mL. For systemic administration, a subject can be administered a therapeutic amount, for example, such as 0.1 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 2.5 mg / kg, 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg or more.
[0145] The administration of the above dosage can be repeated. In certain embodiments, the dosage is administered once a day or multiple times a day, for example but not limited to three times a day. In certain embodiments, the above dosage is administered daily for several weeks or months. The duration of treatment depends on the clinical progress of the subject and the response to treatment.
[0146] In some embodiments, the dose may be about 2 mg / kg to about 15 mg / kg. In some embodiments, the dose may be about 2 mg / kg. In some embodiments, the dose may be about 4 mg / kg. In some embodiments, the dose may be about 5 mg / kg. In some embodiments, the dose may be about 6 mg / kg. In some embodiments, the dose may be about 8 mg / kg. In some embodiments, the dose may be about 10 mg / kg. In some embodiments, the dose may be about 15 mg / kg. In some embodiments, the dose may be about 100 mg / kg. 2 About 700 mg / m 2 In certain embodiments, the dose may be about 250 mg / m 2 In certain embodiments, the dose may be about 375 mg / m 2 In certain embodiments, the dose may be about 400 mg / m 2 In certain embodiments, the dose may be about 500 mg / m 2 .
[0147] In certain embodiments, the dosage can be administered intravenously. In certain embodiments, intravenous administration can be an infusion performed within about 10 minutes to about 3 hours. In certain embodiments, intravenous administration can be an infusion performed within about 30 minutes to about 90 minutes.
[0148] In certain embodiments, the dose may be administered about weekly. In certain embodiments, the dose may be administered weekly. In certain embodiments, the dose may be administered weekly for about 12 weeks to about 18 weeks. In certain embodiments, the dose may be administered about every 2 weeks. In certain embodiments, the dose may be administered about every 3 weeks. In certain embodiments, the dose may be administered about 2 mg / kg to about 15 mg / kg about every 2 weeks. In certain embodiments, the dose may be administered about 2 mg / kg to about 15 mg / kg about every 3 weeks. In certain embodiments, the dose may be administered about 2 mg / kg to about 15 mg / kg intravenously about every 2 weeks. In certain embodiments, the dose may be administered about 2 mg / kg to about 15 mg / kg intravenously about every 3 weeks. In certain embodiments, the dose may be administered about 200 mg / m intravenously about weekly. 2 About 400 mg / m 2 In certain embodiments, the dose may be about 200 mg / m administered intravenously about every 2 weeks. 2 About 400 mg / m 2 In certain embodiments, the dose may be about 200 mg / m administered intravenously about every 3 weeks. 2 About 400 mg / m 2 . In certain embodiments, about 2 doses to about 10 doses are administered in total. In certain embodiments, 4 doses are administered in total. In certain embodiments, 5 doses are administered in total. In certain embodiments, 6 doses are administered in total. In certain embodiments, 7 doses are administered in total. In certain embodiments, 8 doses are administered in total. In certain embodiments, the administration is performed for a total of about 4 weeks to about 12 weeks. In certain embodiments, the administration is performed for a total of about 6 weeks. In certain embodiments, the administration is performed for a total of about 8 weeks. In certain embodiments, the administration is performed for a total of about 12 weeks. In certain embodiments, the initial dose can be about 1.5 to about 2.5 times higher than the subsequent doses.
[0149] In certain embodiments, the dosage may be about 1 mg to about 2000 mg. In certain embodiments, the dosage may be about 3 mg. In certain embodiments, the dosage may be about 10 mg. In certain embodiments, the dosage may be about 30 mg. In certain embodiments, the dosage may be about 1000 mg. In certain embodiments, the dosage may be about 2000 mg. In certain embodiments, the dosage may be about 3 mg administered daily by intravenous infusion. In certain embodiments, the dosage may be about 10 mg administered daily by intravenous infusion. In certain embodiments, the dosage may be about 30 mg administered three times per week by intravenous infusion.
[0150] The therapeutically effective amount is an amount of the agent sufficient to produce a statistically significant measurable change in inflammatory disorders, autoimmune diseases, transplant rejection or GVHD or to prevent the occurrence of inflammatory disorders, autoimmune diseases, transplant rejection or GVHD. Such an effective amount can be measured in clinical trials as well as animal studies.
[0151] The medicament can be administered intravenously by injection or by gradual infusion over time. Given an appropriate formulation for a given route, the medicament used in the methods and compositions described herein can be administered intravenously, intranasally, by inhalation, intraperitoneally, intramuscularly, subcutaneously, intracavitary, and if desired, can also be delivered by peristalsis or by other means known to those skilled in the art. Preferably, the compounds used herein are administered orally, intravenously or intramuscularly. Also under special consideration is local administration, such as direct administration to the site of an organ or tissue transplant.
[0152] For example, a therapeutic composition comprising at least one pharmaceutical agent may be routinely administered in unit doses. When used in relation to therapeutic compositions, the term "unit dose" refers to physically discrete units suitable as unit doses for subjects, each unit containing a predetermined amount of active substance calculated to produce the desired therapeutic effect in combination with the required physiologically acceptable diluent (i.e., carrier or excipient).
[0153] The composition is administered in a manner compatible with the dosage form and in a therapeutically effective amount. The amount and time to be administered will depend on the subject to be treated, the subject's systemic ability to utilize the active ingredient, and the extent of the desired therapeutic effect.
[0154] The exact amount of active ingredient required for administration depends on the judgment of the clinician and varies according to individual circumstances. However, dosage ranges suitable for systemic application are disclosed herein, and the dosage range depends on the route of administration. Suitable administration regimens are also variable, but typically are followed by initial administration followed by repeated administration at intervals of 1 or more hours by subsequent injections or other administrations. Alternatively, continuous intravenous infusions sufficient to maintain the concentration in the blood within the range specified for in vivo treatment are contemplated.
[0155] In certain embodiments, the method further comprises administering a composition, CAR or cell as described herein: one or more additional anti-inflammatory, autoimmune, GVHD or transplant rejection agents, biologics, drugs or treatments as part of a combination therapy. Exemplary treatments for transplant rejection or GVHD include, but are not limited to, immunosuppressive drugs such as cyclosporine (Neoral, Sandimmune, Gengraf and Restasis), tacrolimus (Prograf, Protopic, Astagraf XL and Envarsus XR), methotrexate (Trexall, Rasuvo, Rheumatrex, and Otrexup (PF)), sirolimus (Rapamune), mycophenolic acid (Myfortic and CellCept), rituximab (Rituxan), etanercept (Enbrel), pentostatin (Nipent), ruxolitinib (Jakafi); chemotherapeutic agents, such as methotrexate (Trexall, Rasuvo, Rheumatrex, and Otrexup (PF)), antithymocyte globulin (Atgam, Thymoglobulin); steroids, such as prednisone (Deltasone, Rayos, and Prednisone Intensol), methylprednisolone (Medrol, Solu-Medrol, and Depo-Medrol), budesonide (Entocort EC, Uceris); antifungals, such as posaconazole (Noxafil); antivirals, such as acyclovir (Zovirax and Sitavig), valacyclovir (Valtrex); antibiotics, such as sulfamethoxazole / trimethoprim (Bactrim, Sulfatrim, and Bactrim DS); protease inhibitors, such as alpha 1-proteinase inhibitor (Zemaira); extracorporeal photochemotherapy; monoclonal antibodies (daclizumab (Zinbryta), basiliximab (Simulect)), brentuximab vedotin (Adcetris), alemtuzumab (Campath, Lemtrada), tocilizumab (Actemra); mesenchymal stromal cell infusion.Exemplary treatments for autoimmune diseases include, but are not limited to, insulins such as insulin glulisine (Apidra and ApidraSoloStar), insulin detemir (Levemir and Levemir FlexTouch), insulin aspart (NovoLog, NovologFlexpen, and Novolog PenFill), insulin lispro (Humalog and Humalog KwikPen), insulin, insulin glargine (Lantus, Lantus Solostar, and Toujeo SoloStar); dietary supplements such as glucose tablets; and hormones such as glucagon (GlucaGen and Glucagon Emergency Kit (Human)), antidiabetic agents (metformin (D-Care DM2, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet), glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide (Saxenda; Victoza) or semaglutide (Ozempic) or sodium-glucose co-transporter 2 (SGLT2) inhibitors: empagliflozin (Jardiance), canagliflozin (Invokana); sulfonylureas: glipizide (GlipiZIDE XL, Glucotrol, Glucotrol XL); meglitinide analogs: repaglinide (Prandin); thiazolidinediones: pioglitazone (Actos); dipeptidyl peptidase-4 [DPP-4] inhibitors: sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina)).
[0156] The efficacy of a given treatment (e.g., for inflammatory conditions, autoimmune diseases, transplant rejection, or GVHD) can be determined by a skilled clinician. However, as the term is used herein, if any or all symptoms or signs are changed in a beneficial manner after treatment with a medicament as described herein, or other clinically recognized symptoms are improved or even alleviated (e.g., improved by at least 10%), then treatment is considered to be "effective treatment". As assessed by hospitalization or the need for medical intervention (i.e., disease progression stops), the efficacy can also be measured by the individual not deteriorating. The measurement methods of these indicators are known to those skilled in the art and / or described herein.
[0157] The effective amount for treating a disease means that when administered to a mammal in need, it is sufficient to produce the term defined herein--effective treatment amount. The efficacy of a medicament can be determined by evaluating physical indicators such as autoimmune diseases (e.g., results of ANA), transplant rejection (e.g., high fever, tenderness at the transplant site, etc.), or GVHD (e.g., redness, pain, or other symptoms at the transplant site). The effective amount, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell culture or experimental animals, such as for determining LD50 (lethal dose for 50% of the population) and ED50 (dose effective for treatment in 50% of the population). The dosage can vary depending on the dosage form used and the administration route utilized. The dose ratio between toxicity and therapeutic effect is the therapeutic index, and can be expressed as the ratio of LD50 / ED50. Compositions and methods that preferably exhibit a large therapeutic index. The therapeutically effective dose can be initially evaluated by cell culture assays. In addition, as determined in cell culture or appropriate animal models, dosage can be customized in animal models to achieve a circulating plasma concentration range comprising IC50 (i.e., the concentration of the active ingredient that achieves half-maximal inhibition of symptoms). The level in plasma can be measured by, for example, high performance liquid chromatography. The effect of any particular dosage can be monitored by appropriate bioassays, such as assays for assessing post-transplantation responses, assays for assessing inflammation levels, ANA measurements, etc. Dosage can be determined by a doctor and adjusted as needed to accommodate the observed therapeutic effect.
[0158] Efficacy can also be measured by the lack of deterioration of an individual, as assessed by hospitalization or the need for medical intervention (i.e., cessation of disease progression), for example. Methods for measuring these indicators are known to those skilled in the art and / or described herein. Treatment includes any treatment of a disease in an individual or animal (some non-limiting examples include humans or animals), and includes: (1) inhibiting the disease, such as preventing symptoms from worsening (e.g., pain or inflammation); or (2) reducing the severity of the disease, such as causing a decrease in symptoms. An effective amount for treating a disease means an amount sufficient to produce an effective treatment, as defined herein, for the disease when administered to a subject in need thereof. The efficacy of an agent can be determined by assessing physical indicators of a condition or desired response (e.g., a reduction in inflammation, etc.). Those skilled in the art are fully capable of monitoring the efficacy of administration and / or treatment by measuring any one of these parameters or any combination of parameters. Efficacy can be assessed in animal models of the conditions described herein, such as treatment of inflammatory conditions, autoimmune diseases, transplant rejection, or GVHD. When using an experimental animal model, the efficacy of the treatment is confirmed when a statistically significant change in a marker is observed, such as inflammation.
[0159] In certain embodiments, the technology described herein relates to a pharmaceutical composition comprising a CAR as described herein, and an optional pharmaceutically acceptable carrier. In certain embodiments, the active ingredient of the pharmaceutical composition includes a CAR as described herein. In certain embodiments, the active ingredient of the pharmaceutical composition consists essentially of a CAR as described herein. In certain embodiments, the active ingredient of the pharmaceutical composition consists of a CAR as described herein. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and / or dispersion media. The use of these carriers and diluents is well known in the art. Some non-limiting examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) sugar alcohols, such as propylene glycol; (11) Polyols such as glycerol, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) fillers such as polypeptides and amino acids; (23) serum components such as serum albumin, HDL and LDL; (24) C2-C12 alcohols such as ethanol; and (25) other non-toxic compatible substances used in pharmaceutical preparations. Wetting agents, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants may also be present in the preparation. The terms "excipient," "carrier," "pharmaceutically acceptable carrier," and the like are used interchangeably herein. In certain embodiments, the carrier inhibits degradation of the active agents described herein.
[0160] In certain embodiments, the pharmaceutical composition comprising the CAR described herein can be a parenteral dosage form. Since the administration of parenteral dosage forms typically bypasses the patient's natural defenses against contaminants, the parenteral dosage form is preferably sterile or can be sterilized before administration to the patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable injection vehicle, suspensions ready for injection, and emulsions. In addition, controlled-release parenteral dosage forms can be prepared for administration to patients, including but not limited to Dosage forms and dose dumping.
[0161] Suitable solvents that can be used to provide parenteral dosage forms of the CAR disclosed herein are well known to those skilled in the art. Examples include, but are not limited to, sterile water, USP water for injection, saline solution, glucose solution, aqueous solvents such as, but not limited to, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible solvents such as, but not limited to, ethanol, polyethylene glycol, and propylene glycol; and non-aqueous solvents such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Compounds that change or modify the solubility of a pharmaceutically acceptable salt of an active ingredient may also be incorporated into the parenteral dosage forms of the present disclosure, including conventional and controlled release parenteral dosage forms.
[0162] The pharmaceutical compositions can also be formulated for oral administration, for example as discrete dosage forms such as, but not limited to, tablets (including but not limited to scored or coated tablets), pills, caplets, capsules, chewable tablets, powder packets, cachets, lozenges, wafers, aerosol sprays, or liquids, including but not limited to syrups, elixirs, solutions or suspensions in aqueous liquids, non-aqueous liquids, water-in-oil emulsions, or oil-in-water emulsions. These compositions contain a predetermined amount of a pharmaceutically acceptable salt of a disclosed compound and can be prepared by pharmaceutical methods well known to those skilled in the art. See generally: Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott, Williams and Wilkins, Philadelphia PA. (2005).
[0163] Conventional dosage forms usually provide the rapid or immediate release of drugs from preparations. According to the pharmacology and pharmacokinetics of the drug, the use of conventional dosage forms may cause a significant fluctuation in the drug concentration in the patient's blood and other tissues. These fluctuations may affect multiple parameters, such as the maintenance, toxicity, side effects, etc. of dosing frequency, onset time, efficacy duration, therapeutic blood drug concentration. Advantageously, controlled release formulations can be used to control the onset time, duration, plasma concentration and peak blood drug concentration in the treatment window of the drug. In particular, controlled release or sustained release formulations or preparations can be used to ensure the maximum utility of the drug, and potential adverse reactions and safety issues are minimized at the same time, which may occur due to insufficient drug dosage (i.e., below the minimum treatment level) and exceeding the toxicity level of the drug. In some embodiments, the composition can be given as a sustained release formulation.
[0164] A common goal of controlled-release drug products is to improve drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of optimally designed controlled-release formulations in medical treatments is characterized by using a minimum amount of drug substance to cure or control a condition in the shortest possible time. Advantages of controlled-release formulations include: (1) prolonging the activity of the drug; (2) reducing the frequency of dosing; (3) increasing patient compliance; (4) using a smaller total amount of the drug; (5) reducing local or systemic side effects; (6) minimizing drug accumulation; (7) reducing fluctuations in blood drug levels; (8) improving therapeutic efficacy; (9) reducing enhancement or loss of drug activity; and (10) improving the speed of control of a disease or condition. See Kim, Cherng-ju, Controlled Release Dosage Form Design, 2 (Technomic Publishing, Lancaster, Pa.: 2000).
[0165] Most controlled-release dosage forms are designed to initially release a certain amount of drug (active ingredient) that rapidly produces the desired therapeutic effect, and gradually and continuously release additional amounts of drug to maintain this level of therapeutic or preventive effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that replaces the amount of drug metabolized and excreted from the body. Controlled release of active ingredients can be stimulated by various conditions, including but not limited to pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.
[0166] Various known controlled or sustained-release dosage forms, preparations and devices can be adapted to the salts and compositions of the present disclosure. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770, 3,916,899, 3,536,809, 3,598,123, 4,008,719, 5674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, 5,733,566, and 6,365,185B1, each of which is incorporated herein by reference. These dosage forms can use, for example, hydroxypropyl methylcellulose, other polymer matrices, gels, permeable membranes, permeation systems (e.g. (Alza Corporation, Mountain View, Calif. USA)) or a combination thereof is used to provide sustained or controlled release of one or more active ingredients to provide a desired release profile in different ratios.
[0167] For convenience, the meanings of certain terms and phrases used in the specification, examples, and appended claims are provided below. Unless otherwise specified or implied from the context, the following terms and phrases include the meanings provided below. These definitions are provided to help describe specific embodiments and are not intended to limit the claimed invention, as the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as the common sense understanding of a person of ordinary skill in the art to which the invention belongs. If the use of a term in this field is significantly different from its definition provided herein, the definition provided in the specification shall prevail.
[0168] For convenience, certain terms used herein in the specification, examples, and appended claims are collected here.
[0169] The terms "reduce", "lower", "reduce" or "inhibit" are all used herein to refer to a statistically significant amount of reduction. In certain embodiments, "reduce", "reduce", or "reduce" or "inhibit" generally refers to a reduction of at least 10% compared to a reference level (e.g., in the absence of a given treatment), and can include, for example, a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. "Reduce" or "inhibit" used herein does not include complete inhibition or reduction relative to a reference level. "Complete inhibition" is 100% inhibition relative to a reference level. Reduction can preferably be reduced to a level within the range accepted as normal for individuals without a given disorder.
[0170] The terms "increase", "elevate", "enhance" or "activate" are all used herein to refer to an increase in a statistically significant amount. In certain embodiments, the terms "increase", "elevate", "enhance" or "activate" may refer to an increase of at least 10% compared to a reference level, such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including an increase of 100%, or any increase between 10%-100% compared to a reference level, or at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times, or at least about 10 times, or any increase between 2 times to 10 times or more compared to a reference level. In the context of a marker or symptom, "increase" refers to an increase that is statistically significant at the level.
[0171]
[00136] The terms "improvement" or "improvement" when applied to scores on a standardized scale or score (eg, for disease symptoms or severity) refer to a statistically significant, favorable change on that scale or score.
[0172] As used herein, "reference level" refers to the level or value of a given parameter against which the level or value in a given sample or situation is compared to determine whether the level or value has changed in a meaningful way. The reference level can be the level in a sample that has not been treated to change the parameter or the level from the sample. Alternatively, the reference level can be the level in a normal sample or an unaffected sample or the level from the sample. Alternatively, the reference level can be the level in a sample obtained from a subject at a previous time point (e.g., before a given treatment) or the level from the sample.
[0173] "Subject" used herein refers to humans or animals. Typically, animals are vertebrates, such as primates, rodents, livestock or game animals. Primates include chimpanzees, crab-eating monkeys, spider monkeys and macaques, such as rhesus monkeys. Rodents include mice, rats, marmots, ferrets, rabbits and hamsters. Livestock and game animals include cows, horses, pigs, deer, bison, buffaloes, felines (such as house cats), canines (such as dogs, foxes, wolves), birds (such as chickens, emus, ostriches) and fish (such as trout, catfish and salmon). In certain embodiments, the subject is a mammal, such as a primate, such as humans. The terms "individual", "patient" and "subject" are used interchangeably herein.
[0174] Preferably, the subject is a mammal. The mammal may be a human, non-human primate, mouse, rat, dog, cat, horse or cow, but is not limited to these examples. Mammals other than humans may be advantageously used as subjects representing animal models of inflammatory conditions, autoimmune diseases, transplant rejection or GVHD. The subject may be male or female.
[0175] The subject may be previously diagnosed as having or identified as having or having a condition (e.g., inflammatory condition, autoimmune disease, transplant rejection or GVHD) or one or more complications associated with such conditions that require treatment, and optionally, has experienced inflammatory condition, autoimmune disease, transplant rejection or GVHD or the treatment of one or more complications associated with inflammatory condition, autoimmune disease, transplant rejection or GVHD. Alternatively, the subject may also be a subject that has not been previously diagnosed as having inflammatory condition, autoimmune disease, transplant rejection or GVHD or one or more complications associated with inflammatory condition, autoimmune disease, transplant rejection or GVHD. For example, the subject may be a subject that exhibits one or more risk factors for one or more complications associated with inflammatory condition, autoimmune disease, transplant rejection or GVHD, or a subject that does not exhibit risk factors.
[0176] A "subject in need of treatment" for a particular disorder can be a subject having, diagnosed as having, or at risk of developing the disorder, eg, an inflammatory disorder, an autoimmune disease, transplant rejection, or GVHD.
[0177] As used herein, "appropriate control" refers to untreated, otherwise identical cells or populations (e.g., subjects not administered an agent described herein, or only a subset of subjects administered an agent described herein, relative to non-control cells).
[0178] In certain embodiments, the nucleic acid encoding CAR as described herein is contained in a vector. In certain aspects described herein, the nucleic acid sequence encoding CAR as described herein or any module thereof is operably connected to another sequence, such as a promoter in a vector. The term "vector" used herein refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. The vector used herein may be viral or non-viral. The term "vector" is included in any genetic element that can replicate and transfer a gene sequence to a cell when associated with an appropriate control element. The vector may include, but is not limited to, a cloning vector, an expression vector, a plasmid, a bacteriophage, a transposon, a clay, a chromosome, a virus, a virion, etc.
[0179] As used herein, the term "expression vector" refers to a vector that directs the expression of RNA or polypeptides from a sequence of transcriptional regulatory sequences connected to the vector. The expressed sequence is usually, but not necessarily, heterologous to the cell. The expression vector may contain additional elements, for example, the expression vector may have two replication systems, thereby allowing it to be maintained in two organisms, such as for expression in human cells and for cloning and amplification in prokaryotic hosts. The term "expression" refers to the cellular process involved in the production of RNA and proteins, and secretion of proteins under appropriate circumstances, including (where applicable) but not limited to, for example, transcription, transcription processing, translation and protein folding, modification and processing. "Expression products" include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" refers to a nucleic acid sequence that is transcribed (DNA) into RNA in vitro or in vivo when operably linked to an appropriate regulatory sequence. A gene may or may not include regions before and after the coding region, such as 5' untranslated (5'UTR) or "leader" sequence and 3'UTR or "trailer" sequence, as well as insertion sequences (introns) between individual coding fragments (exons).
[0180] As used herein, the term "viral vector" refers to a nucleic acid vector construct comprising at least one element of viral origin and having the ability to be packaged into viral vector particles. The viral vector may comprise a nucleic acid encoding a CAR as described herein, replacing non-essential viral genes. The vector and / or particle may be used for the purpose of transferring any nucleic acid into a cell in vitro or in vivo. Numerous forms of viral vectors are well known in the art.
[0181] By "recombinant vector" is meant a vector comprising a heterologous nucleic acid sequence or a "transgene" capable of being expressed in vivo. It should be understood that the vectors described herein can be combined with other suitable compositions and therapies in certain embodiments. In certain embodiments, the vector is an additional type. The use of a suitable additional vector provides a means for maintaining the nucleotide of interest in a subject with a high copy number of extrachromosomal DNA, thereby eliminating the potential effects of chromosomal integration.
[0182] As used herein, the term "nucleic acid" or "nucleic acid sequence" refers to any molecule, preferably a polymeric molecule, incorporating units of ribonucleic acid, deoxyribonucleic acid or their analogs. The nucleic acid can be single-stranded or double-stranded. A single-stranded nucleic acid can be one nucleic acid strand of a denatured double-stranded DNA. Alternatively, it can be a single-stranded nucleic acid that is not derived from any double-stranded DNA. In one aspect, the nucleic acid can be DNA. In another aspect, the nucleic acid can be RNA. Suitable nucleic acid molecules are DNA, including genomic DNA or cDNA. Other suitable nucleic acid molecules are RNA, including mRNA.
[0183] As used herein, the terms "protein" and "polypeptide" are used interchangeably herein and refer to a series of amino acid residues connected to each other by peptide bonds between the α-amino and carboxyl groups of adjacent residues. The terms "protein" and "polypeptide" refer to polymers of amino acids, including modified amino acids (e.g., phosphorylation, saccharification, glycosylation, etc.) and amino acid analogs, regardless of their size or function. "Protein" and "polypeptide" are generally used to refer to relatively large polypeptides, while the term "peptide" is generally used to refer to small polypeptides, but the use of these terms in this field overlaps. When referring to gene products and fragments thereof, the terms "protein" and "polypeptide" are used interchangeably herein. Therefore, exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologues, orthologues, paralogues, fragments, and other equivalents, variants, fragments, and analogs of the aforementioned.
[0184] As used herein, "antibody" refers to IgG, IgM, IgA, IgD or IgE molecules or antigen-specific antibody fragments thereof (including but not limited to Fab, F(ab')2, Fv, disulfide-linked Fv, scFv, single domain antibodies, multispecific antibodies in closed conformation, disulfide-linked scFv, bispecific antibodies), whether derived from any species that naturally produces antibodies or created by recombinant DNA technology; whether isolated from serum, B cells, hybridomas, transfectomas, yeast or bacteria.
[0185] As used herein, an "antigen" is a molecule that is bound by a binding site on an antibody agent. Typically, an antigen is bound by an antibody ligand and is capable of eliciting an antibody response in vivo. An antigen can be a polypeptide, protein, nucleic acid or other molecule or portion thereof. The term "antigenic determinant" refers to an epitope on an antigen that is recognized by an antigen binding molecule, and more particularly, by the antigen binding site of the molecule.
[0186] As used herein, the term "antibody reagent" refers to a polypeptide comprising at least one immunoglobulin variable domain or immunoglobulin variable domain sequence and specifically binding to a given antigen.Antibody reagents may include antibodies or polypeptides comprising the antigen-binding domains of antibodies.In certain embodiments, antibody reagents may include monoclonal antibodies or polypeptides comprising the antigen-binding domains of monoclonal antibodies.For example, antibodies may include heavy chain (H) variable regions (abbreviated as VH herein) and light chain (L) variable regions (abbreviated as VL herein).In another example, antibodies include two heavy chain (H) variable regions and two light chain (L) variable regions.The term "antibody reagent" includes antigen-binding fragments of antibodies (e.g., single-chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv and domain antibodies (dAb) fragments (see, e.g., de Wildt et al., Eur J. Immunol. 1996; 26(3): 629-39, incorporated herein by reference in their entirety)), as well as complete antibodies. Antibodies can have structural features of IgA, IgG, IgE, IgD, IgM (and subtypes and combinations thereof). Antibodies can be from any source, including mice, rabbits, pigs, rats, and primates (human and non-human primates) and primatized antibodies. Antibodies also include midibodies, humanized antibodies, chimeric antibodies, etc.
[0187] The VH and VL regions can be further subdivided into hypervariable regions called "complementarity determining regions" ("CDRs"), interspersed with more conserved regions called "framework regions" ("FRs"). The extent of the framework regions and CDRs has been precisely defined (see Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al., (1987) J. Mol. Biol. 196: 901-917, incorporated herein by reference in their entirety). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0188] The terms "antigen binding fragment" or "antigen binding domain" are used interchangeably herein to refer to one or more fragments of a full-length antibody that retain the ability to specifically bind to a target of interest. Examples of binding fragments included in the term "antigen binding fragment" of a full-length antibody include: (i) a Fab fragment, a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) a Fd fragment, consisting of VH and CH1 domains; (iv) a Fv fragment, consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546, incorporated herein by reference in its entirety), consisting of a VH or VL domain; and (vi) an isolated complementary determining region (CDR) that retains specific antigen binding function.
[0189] As used herein, the term "specific binding" refers to a chemical interaction between two molecules, compounds, cells and / or particles, wherein the first entity binds to the second target entity with greater specificity and affinity than it binds to a non-target third entity. In certain embodiments, specific binding may refer to an affinity of the first entity for the second target entity that is at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, or more higher than the affinity of the first entity for the non-target third entity. An agent specific for a given target is one that exhibits specific binding to that target under the assay conditions used.
[0190] In addition, and as described herein, recombinant humanized antibodies can be further optimized to reduce potential immunogenicity while maintaining functional activity for use in human therapy. In this regard, functional activity refers to the ability of a polypeptide to exhibit one or more known functional activities associated with a recombinant antibody or antibody reagent as described herein. Such functional activity includes, for example, the ability to bind to a target.
[0191] As used herein, the terms "treat", "treatment", "treatment" or "improvement" refer to therapeutic treatment, the goal of which is to reverse, alleviate, relieve, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder, such as an inflammatory response, an autoimmune disease, transplant rejection or GVHD. The term "treatment" includes reducing or alleviating at least one adverse effect or symptom of a condition associated with a disease or disorder, such as an inflammatory response, an autoimmune disease, transplant rejection or GVHD. Generally, treatment is "effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is "effective" if the progression of the disease is reduced or stopped. That is, "treatment" includes not only the improvement of symptoms or markers, but also the cessation or at least slowing down of the progression or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviating one or more symptoms, reducing the extent of the disease, stabilizing (i.e., not worsening) the disease state, delaying or slowing the progression of the disease, improving or alleviating the disease state, alleviating (whether partially or completely), and / or reducing mortality (whether detectable or not). The term "treatment" of a disease also includes providing relief from the symptoms or side effects of the disease (including palliative care).
[0192] As used herein, the term "pharmaceutical composition" refers to an active agent in combination with a pharmaceutically acceptable carrier (e.g., a carrier commonly used in the pharmaceutical industry). The phrase "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human or animal tissues without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable risk / benefit ratio, within the scope of sound medical judgment.
[0193] As used herein, the term "administering" refers to placing an agent disclosed herein (e.g., CAR, composition, or cell) into a subject by a method or approach that allows the agent to be at least partially delivered to a desired site. A pharmaceutical composition comprising a compound disclosed herein can be administered by any suitable route that results in effective treatment in a subject.
[0194] The term "statistically significant" or "significantly" refers to statistical significance, and typically refers to a difference of two standard deviations (2SD) or greater.
[0195] Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein are to be understood as modified in all instances by the term “about.” When used in conjunction with a percentage, the term “about” may mean ±1%.
[0196] As used herein, the terms "comprising" or "including" are used to refer to components that are essential to a method or composition, a method, and their respective components, but remain open to the inclusion of unspecified elements, whether essential or not.
[0197] The term "consisting of refers to the compositions, methods, and respective components thereof as described herein, excluding any elements not recited in the description of the embodiment.
[0198] As used herein, the term "consisting essentially of refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristics of the embodiment.
[0199] The singular terms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Likewise, the word "or" is intended to include "or" unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin "exempli gratia" and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg" is synonymous with the term "for example".
[0200] Unless otherwise defined herein, the scientific and technical terms used in connection with the present application shall have the meanings commonly understood by those of ordinary skill in the art. It will be understood that the present invention is not limited to the specific methods, protocols and reagents described herein, and therefore may be different. The terms used herein are only used to describe the purpose of specific embodiments, and are not intended to limit the scope of the present invention, which is limited only by the claims. Definitions of common terms in immunology and molecular biology can be found in: The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Werner Luttmann, Immunology, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (Ed.), Taylor&FrancisLimited, 2014 (ISBN 0815345305,9780815345305); Lewin's Genes XI, Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Manual, 4th Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, published by Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (editor), Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (Ed.), John Wiley and Sons, 2014 (ISBN047150338X, 9780471503385); Current Protocols in Protein Science (CPPS), John E. Coligan (Ed.), John Wiley and Sons Published by Sons, Inc., 2005; and Current Protocols in Immunology (CPI), John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe (eds.), John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are incorporated herein by reference in their entirety.
[0201] Other terms are defined in the description of various aspects herein.
[0202] All patents and other publications (including literature references, issued patents, published patent applications, and pending patent applications) cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, that the methodologies described in such publications may be used in conjunction with the techniques described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the dates or contents of these documents are based on the information available to the applicants and do not constitute any admission as to the correctness of the dates or contents of these documents.
[0203] The description of the embodiments of the present disclosure is not intended to be exhaustive of the present disclosure or to limit it to the precise form disclosed. Although specific embodiments and examples of the present disclosure are described herein for illustrative purposes, various equivalent modifications may be made within the scope of the present disclosure, as will be recognized by those skilled in the relevant art. For example, although the method steps or functions are presented in a given order, alternative embodiments may perform functions in different orders, or functions may be performed substantially in parallel. The teachings of the disclosure provided herein may be applied to other programs or methods, as appropriate. Various embodiments described herein may be combined to provide further embodiments. If necessary, various aspects of the present disclosure may be modified to provide further embodiments of the present disclosure using the compositions, functions and concepts of the above-mentioned references and applications. In addition, due to considerations of biological functional equivalence, some changes may be made in protein structure without affecting biological or chemical effects in terms of type or amount. In view of the detailed description, these and other changes may be made to the present disclosure. All these modifications are intended to be included within the scope of the appended claims.
[0204] The specific elements of any of the foregoing embodiments may be combined or replace the elements in other embodiments. In addition, although the advantages associated with certain embodiments of the present disclosure are described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments must exhibit these advantages to fall within the scope of the present disclosure.
[0205] In some embodiments, the present technology can be defined by any of the following numbered paragraphs: 1. A chimeric antigen receptor (CAR) polypeptide, comprising from N-terminus to C-terminus: a) specifically binds to the extracellular recognition portion of OX40L; b) a transmembrane portion; and c) Intracellular signal transduction part. 2. The CAR described in paragraph 1, wherein the C-terminus of the intracellular signaling portion further comprises a detectable polypeptide. 3. The CAR described in paragraph 2, wherein the detectable polypeptide is a fluorescent polypeptide. 4. The CAR described in paragraph 3, wherein the fluorescent polypeptide is NeonGreen. 5. The CAR of any one of paragraphs 2-4, further comprising a cleavage site between the intracellular signaling portion and the detectable polypeptide. 6. The CAR of paragraph 5, wherein the cleavage site is a cleavable T2A site or a tandem P2A-T2A site. 7. The CAR of any of the preceding paragraphs, wherein the recognition portion is an antibody reagent or a ligand functional domain. 8. The CAR of paragraph 7, wherein the antibody reagent is scFV. 9. The CAR of any of paragraphs 7-8, wherein the antibody agent is an anti-OX40L antibody agent. 10. The CAR of paragraph 9, wherein the antibody reagent comprises a CDR sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the 6 CDRs of SEQ ID NOs: 1-6. 11. The CAR of paragraph 9, wherein the antibody reagent comprises a sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the amino acid sequence of SEQ ID NOs: 7-12. 12. The CAR of any of paragraphs 1-11, wherein the intracellular signaling portion comprises one or more of the following: a CD28 co-signaling domain, a 41BB co-signaling domain, an IL2RαJAK3 and IL2RβSTAT5 composite docking site, a TGFβ-R SMAD2 / 3 docking site, and a CD3ζ signaling domain. 13. The CAR of any of paragraphs 1-11, wherein the intracellular signaling portion comprises a CD28 co-signaling domain and a CD3ζ domain. 14. The CAR of any of paragraphs 1-11, wherein the intracellular signaling portion comprises a 41BB co-signaling domain and a CD3ζ domain. 15. A nucleic acid molecule encoding the CAR of any one of the preceding claims. 16. The nucleic acid molecule of paragraph 15, wherein the expression of the CAR is controlled by a Treg-specific promoter or a MND promoter. 17. The nucleic acid molecule of paragraph 16, wherein the Treg-specific promoter comprises a FoxP3 promoter or a hybrid promoter of FoxP3 and IKZF2 / Helios. 18. A vector comprising the nucleic acid molecule of any one of paragraphs 15-17. 19. A cell comprising the CAR of any one of paragraphs 1-14, or the nucleic acid molecule or vector of any one of claims 15-18. 20. The cell of paragraph 19, wherein the cell is a Treg. 21. The cell of paragraph 20, wherein the Treg expresses Foxp3. 22. The cell of paragraph 20, wherein the Treg expresses CD4 and CD25. 23. A population of cells, at least 80% of which are cells as described in paragraph 19. 24. A method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject the cell or cell population of any of paragraphs 19-23. 25. The method of paragraph 24, wherein the autoimmune disorder or inflammatory disorder comprises allogeneic transplant rejection or xenogeneic transplant rejection, or graft-versus-host disease (GVHD). 26. The method of paragraph 24, wherein the autoimmune disorder or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection and inflammatory disorders. 27. The method of paragraphs 24-26, wherein the Treg population is autologous to the subject. 28. The method of paragraphs 24-26, wherein the Treg population is allogeneic to the subject. 29. The cell or cell population of any of paragraphs 19-23 for use in a method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof, the method comprising administering the cell or cell population to the subject. 30. The cell or cell population of paragraph 24, wherein the autoimmune or inflammatory disorder comprises allogeneic transplant rejection or xenogeneic transplant rejection, or graft-versus-host disease (GVHD). 31. The cell or cell population of paragraph 24, wherein the autoimmune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection and inflammatory disorders. 32. The cell or cell population of paragraphs 24-26, wherein the Treg population is autologous to the subject. 33. The cell or cell population of paragraphs 24-26, wherein the Treg population is allogeneic to the subject. Example Example 1
[0206] The inventors have designed and constructed several chimeric antigen receptor (CAR) constructs, for example, connecting the single-chain fragment variant antigen binding fragment of an anti-OX40L antibody to intracellular CD3ζ and 4-1BB or CD28 signaling domains. A construct further connected to a fluorescent protein reporter NeonGreen was also designed to express visualization. In some of the constructs described herein, the expression of the construct is controlled by connecting a Treg-specific promoter or by connecting a nonspecific MND promoter. These OX40L-CAR constructs have been successfully transduced into Jurkat lymphoid cells and human FACS-purified CD25+CD127-Treg cells ( Figure 1A-1B and Figure 7 ). The OX40L-CAR construct was expressed in a Treg-specific manner, and expression of the CAR did not interfere with the ex vivo expansion of Tregs ( Figure 1C-Figure 1D , Figure 2A-2D , Figure 8A-B and Figure 9A-9B Stimulation of Treg cells transduced with the OX40L-CAR construct induced Treg activation markers at levels comparable to TCR stimulation ( Figure 3A In addition, the stimulation induced the production of inhibitory proteins (e.g., IL-2, CTLA4, LAG-3, GARP, and LAP) but did not induce the production of proinflammatory cytokines (e.g., IL17A, TNFa, and IFNg) ( Figure 3B and Figure 10A-10B ). The OX40L-CAR construct can successfully mediate T suppressive activity ( Figure 3C ). These data indicate that CAR-Treg cells retain function and have T suppressive function. Figure 4 The model provided in illustrates this functionality.
[0207] Blocking the interaction between OX40L and OX40 with anti-hOX40L antibodies can effectively prevent and treat aGVHD by interfering with the cytolytic activity of CD8+ T cells. Figure 5A-Figure 5B and Figure 6 ). This article demonstrates that OX40L-CAR-Tregs suppress T cell proliferation in vitro compared to Neon-Tregs. In addition, OX40L-CAR-Tregs showed a higher ability to suppress monocyte-derived dendritic cell activation, highlighting the superior suppressive activity of these OX40L-CAR-Tregs compared to non-targeted Neon-Tregs ( Figure 11A-11B and Figure 12A-12B Importantly, in a human xenograft model of GvHD, human PBMCs were transplanted into sublethally irradiated NOD.Cg-Prkdc scid Iq tm1Wjl OX40L CAR-Tregs induced in WT / SzJ(NSG) mice showed superior GvHD disease control compared with both PBMCs and Neon-Tregs alone ( Figure 13A-13B ). The clinical scores assessed by the combined system included five parameters: weight loss, posture, mobility, skin and hair condition, and the curves were compared using a two-way ANOVA mixed effects analysis, which showed improvements in clinical xenogeneic GvHD for OX40L CAR-Treg>Neon-Treg>PBMC alone throughout the analysis period (p<0.001). An example of a substantial improvement in the clinical score on day +14 is as follows: the comprehensive GvHD clinical score, PBMC was 6.5, compared to 2.5 for Neon-Treg, and 0.15 for OX40L CAR-Treg, all comparisons p<0.0001. This control of clinical GvHD resulted in prolonged recipient survival when compared to both PBMC alone and control Neon-Tregs (MST = 34 days for OX40L-CAR-Treg, 20 days for Neon-Treg, and 14 days for PBMC alone, p<0.001).
[0208] In conclusion, these results demonstrate that the approach of using OX40L-CAR Tregs to enhance Treg suppressive function and control GvHD is novel and effective. Since OX40L is upregulated on APCs in an inflammatory setting and its expression is restricted to APCs and activated endothelial cells, this approach provides a unique strategy for the control of allogeneic immunity after HCT. In addition, these OX40L-CAR Tregs can be widely applied beyond HCT to control allogeneic immunity after solid organ transplantation and suppress T cell activation in autoimmune diseases. Example 2 FOXP3 regulatory elements for CAR-Tregs:
[0209] The endogenous FOXP3 promoter contains at least four highly conserved regulatory elements that are located across a large region of the FOXP3 gene [1]. These elements are identified as the FOXP3 core promoter sequence and three other conserved non-coding sequences (CNS1-3). CNS1 is also known as the TGF-β sensor / enhancer, CNS2 is also known as the Treg cell-specific demethylation region (TSDR), and CNS3 is known as the FOXP3 pioneer element. These four regulatory elements play a unique role in the stability and strict control of FOXP3 expression in regulatory T (Treg) cells. When Treg cells receive signals from TCR and CD28 stimulation, these signals induce the activation of several transcription factors (including NFAT, c-Rel and AP-1), which bind to the FOXP3 core promoter sequence and CNS3 of the FOXP3 gene and initiate FOXP3 transcription. In contrast, CNS2 plays a crucial role in maintaining FOXP3 expression. It contains CpG islands that are highly demethylated by the AML1 / RUNX1 complex, which promotes DNA demethylation in this region, and thus this region is also known as TSDR. The demethylated TSDR further recruits STAT5 from other transcription factors induced by IL-2 signaling and TCR / CD28 stimulation to stabilize FOXP3 transcription. TGF-β-induced SMAD2 / 3 gene expression, which is also actively involved in FOXP3 gene expression, occurs through TGF-β binding to CNS1.
[0210] Since the natural FOXP3 promoter is too large to be used directly as part of a gene expression cassette in a lentiviral vector, the inventors used a human synthetic FOXP3 promoter to selectively drive OX40LCAR gene expression in Treg cells. The inventors designed this promoter using the same design previously published for restoring lineage-specific FoxP3 expression in mouse HSCs [2]. Finally, the inventors cloned all three CNS enhancer elements and placed them in series upstream of the FOXP3 core promoter sequence. In addition, the inventors included the 5′ and 3′ untranslated regions (or UTRs) of FOXP3 before and after the CAR gene cassette to maintain any potential post-transcriptional regulation of the FOXP3 transcript. Under the control of the synthetic human FOXP3 promoter, the OX40L CAR protein is more selectively expressed on Treg cells rather than on rare conventional T (Tcon) cells, which can be amplified in small quantities during Treg purification. References: 1.Colamatteo A,Carbone F,Bruzzaniti S,Galgani M,Fusco C,ManiscalcoGT,Di Rella F,de Candia P,De Rosa V.Molecular Mechanisms Controlling Foxp3Expression in Health and Autoimmunity:From Epigenetic to Post-translationalRegulation.Front Immunol.2020;10:3136. 2Masiuk KE,Laborada J,Roncarolo MG,Hollis RP,Kohn DB.Lentiviral GeneTherapy in HSCs Restores Lineage-Specific Foxp3 Expression and SuppressesAutoimmunity in a Mouse Model of IPEX Syndrome.Cell Stem Cell.2019;24(2):309-317.e7
Claims
1. A chimeric antigen receptor (CAR) polypeptide, comprising from N-terminus to C-terminus: a) specifically binds to the extracellular recognition portion of OX40L; b) a transmembrane portion; and c) Intracellular signal transduction part.
2. The CAR according to claim 1, wherein the C-terminus of the intracellular signaling portion further comprises a detectable polypeptide.
3. The CAR according to claim 2, wherein: The detectable polypeptide is a fluorescent polypeptide.
4. The CAR according to claim 3, wherein: The fluorescent polypeptide is NeonGreen.
5. The CAR according to any one of claims 2-4, further comprising a cleavage site between the intracellular signaling moiety and the detectable polypeptide.
6. The CAR according to claim 5, wherein: The cleavage site is a cleavable T2A site or a tandem P2A-T2A site.
7. A CAR according to any one of the preceding claims, wherein: The recognition portion is an antibody reagent or a ligand functional domain.
8. The CAR according to claim 7, wherein: The antibody reagent is scFV.
9. The CAR according to any one of claims 7 or 8, wherein The antibody reagent is an anti-OX40L antibody reagent.
10. The CAR according to claim 9, wherein: The antibody reagent comprises CDR sequences that are at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the six CDRs of SEQ ID NOs: 1-6.
11. The CAR according to claim 9, wherein: The antibody reagent comprises a sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the amino acid sequence of SEQ ID NOs: 7-12.
12. The CAR according to any one of claims 1 to 11, wherein: The intracellular signaling portion comprises one or more of the following: a CD28 co-signaling domain, a 41BB co-signaling domain, an IL2RαJAK3 and IL2RβSTAT5 composite docking site, a TGFβ-RSMAD2 / 3 docking site, and a CD3ζ signaling domain.
13. The CAR according to any one of claims 1 to 11, wherein The intracellular signaling portion comprises a CD28 co-signaling domain and a CD3 zeta domain.
14. The CAR according to any one of claims 1 to 11, wherein The intracellular signaling portion comprises a 41BB co-signaling domain and a CD3 zeta domain.
15. A nucleic acid molecule encoding the CAR according to any one of the preceding claims.
16. The nucleic acid molecule according to claim 15, wherein The expression of the CAR is controlled by a Treg-specific promoter or a MND promoter.
17. The nucleic acid molecule according to claim 16, wherein The Treg-specific promoter comprises FoxP3 promoter or FoxP3 and IKZF2 / Helios hybrid promoter.
18. A vector comprising the nucleic acid molecule according to any one of claims 15-17.
19. A cell comprising a CAR according to any one of claims 1-14, or a nucleic acid molecule or vector according to any one of claims 15-18.
20. The cell according to claim 19, wherein The cells are Tregs.
21. The cell according to claim 20, wherein The Tregs express FoxP3.
22. The cell according to claim 20, wherein The Tregs express CD4 and CD25.
23. A population of cells, at least 80% of which are cells according to claim 19.
24. A method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a cell or cell population according to any one of claims 19-23.
25. The method according to claim 24, wherein: The autoimmune or inflammatory disorder includes allogeneic transplant rejection, xenogeneic transplant rejection, or graft-versus-host disease (GVHD).
26. The method according to claim 24, wherein: The autoimmune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection and inflammatory disorders.
27. The method according to claims 24-26, wherein: The Treg population is autologous to the subject.
28. The method according to claims 24-26, wherein: The Treg population is allogeneic to the subject.
29. A cell or cell population according to any one of claims 19-23 for use in a method of treating an autoimmune disorder or an inflammatory disorder in a subject in need thereof, the method comprising administering the cell or cell population to the subject.
30. The cell or cell population according to claim 24, wherein The autoimmune or inflammatory disorder includes allogeneic or xenogeneic transplant rejection, or graft-versus-host disease (GVHD).
31. The cell or cell population according to claim 24, wherein The autoimmune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes or autoimmune insulitis, multiple sclerosis, autoimmune thyroiditis, autoimmune gastritis, autoimmune uveitis or uveoretinitis, autoimmune orchitis, autoimmune oophoritis, psoriasis, vitiligo, autoimmune prostatitis, any undesirable immune response, tissue rejection and inflammatory disorders.
32. The cell or cell population according to claims 24-26, wherein: The Treg population is autologous to the subject.
33. The cell or cell population according to claims 24-26, wherein: The Treg population is allogeneic to the subject.
